<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2014-08-08T19:06:11Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:aveo="http://www.aveopharma.com/20140630" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="aveo-20140630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE672770--1410-Q0005_STD_0_20100528_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_EA69E0BE-387B-4848-A2B6-D8F1E1C0F289_2_0">25000000</us-gaap:DebtInstrumentFaceAmount>
  <aveo:DebtInstrumentInterestRateAdditionalInterestDeductedFromBaseRate contextRef="eol_PE672770--1410-Q0005_STD_0_20100528_0" unitRef="pure" decimals="INF" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_1_3">0.0475</aveo:DebtInstrumentInterestRateAdditionalInterestDeductedFromBaseRate>
  <aveo:DebtInstrumentInterestRateBaseRate contextRef="eol_PE672770--1410-Q0005_STD_0_20100528_0" unitRef="pure" decimals="INF" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_1_2">0.119</aveo:DebtInstrumentInterestRateBaseRate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE672770--1410-Q0005_STD_0_20100528_0_711502x711169" unitRef="pure" decimals="INF" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_2001_1">0.119</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <aveo:MilestonePaymentsMaximumAmount contextRef="eol_PE672770--1410-Q0005_STD_0_20120731_0_705999x884889_712375x707810" unitRef="iso4217_USD" decimals="-5" id="id_4941002_8DDA650A-7796-4212-B834-87A189A88625_1001_0">9200000</aveo:MilestonePaymentsMaximumAmount>
  <aveo:FundingCommitments contextRef="eol_PE672770--1410-Q0005_STD_0_20140430_0_705999x891464_711502x716112_712375x891398" unitRef="iso4217_USD" decimals="-6" id="id_4941002_7B272764-5407-4261-AD6C-FB143212496D_1001_0">15000000</aveo:FundingCommitments>
  <aveo:PotentialRoyaltyPaymentAsPercentageOfNetSales contextRef="eol_PE672770--1410-Q0005_STD_0_20140430_0_705999x891464_712375x891398" unitRef="pure" decimals="2" id="id_4941002_25BCAC65-4758-4CF9-BE01-04DC98A73A7C_1001_0">0.10</aveo:PotentialRoyaltyPaymentAsPercentageOfNetSales>
  <aveo:PercentageOfProjectCost contextRef="eol_PE672770--1410-Q0005_STD_0_20140430_0_705999x891464_712375x891398" unitRef="pure" decimals="2" id="id_4941002_7B272764-5407-4261-AD6C-FB143212496D_2001_1">0.50</aveo:PercentageOfProjectCost>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE672770--1410-Q0005_STD_0_20140801_0" unitRef="shares" decimals="INF" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_2_5">52297026</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE672770--1410-Q0005_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_EA69E0BE-387B-4848-A2B6-D8F1E1C0F289_1004_0">26500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE672770--1410-Q0005_STD_0_20100602_0" unitRef="shares" decimals="INF" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2002_2">156641</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE672770--1410-Q0005_STD_0_20100602_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2002_3">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:DeferredRevenue contextRef="eol_PE672770--1410-Q0005_STD_0_20110331_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2006_1">4800000</us-gaap:DeferredRevenue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1002_34">33822000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_35">52303000</us-gaap:CommonStockSharesIssued>
  <us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="Investment" decimals="INF" id="id_4941002_CE215435-22DE-475E-A8FC-34882ADB6D62_1_1">5</us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" xsi:nil="true" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_31" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_3001_400008">2401542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="pure" decimals="INF" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2005_10">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="Securities" decimals="INF" id="id_4941002_CE215435-22DE-475E-A8FC-34882ADB6D62_1_2">0</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_3001_6">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_3001_400006">6243190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_28">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" xsi:nil="true" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_30" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_3001_7">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_3001_8">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_34">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_33">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_29">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:LossContingencyPendingClaimsNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="LegalMatter" decimals="INF" id="id_4941002_ACBEBFF9-51B4-47A8-9FFF-739A93BA48F7_1001_0">2</us-gaap:LossContingencyPendingClaimsNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_3001_400007">3416319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_36">52303000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_23">128000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_21">32997000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_38">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_2">2347000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_7">1288000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_37">498602000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_15">3500000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_4">485000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_22">3088000</us-gaap:LongTermLoansPayable>
  <us-gaap:StockholdersEquity contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_40">46958000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_39">-451698000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_18">1128000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_17">11096000</us-gaap:LoansPayableCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_27">0</us-gaap:PreferredStockValue>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_6">34000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_16">16193000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_D911327E-F16B-410C-B580-0AD0EFF60F22_1_2">15464000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_25">7646000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_D911327E-F16B-410C-B580-0AD0EFF60F22_1_1">9309000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebt contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_9E27D0DB-DF2D-4F10-9F76-860640E633C8_1_3">14300000</us-gaap:LongTermDebt>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_D911327E-F16B-410C-B580-0AD0EFF60F22_1_3">1182000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_D911327E-F16B-410C-B580-0AD0EFF60F22_1_0">6155000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_24">13430000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_32">52000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_20">1080000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_41">104247000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_10">97000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_6">687000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1003_1">21573000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_11">2863000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_4">1235000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1003_1">8936000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_9">15863000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_12">104247000</us-gaap:Assets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_4941002_2DBFC9EF-B828-4F29-A4EB-AC4DCCA76BC8_1001_3">204403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1001_34">43362000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CE215435-22DE-475E-A8FC-34882ADB6D62_1_0">8900000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_4941002_2DBFC9EF-B828-4F29-A4EB-AC4DCCA76BC8_1001_4">155461</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_4941002_2DBFC9EF-B828-4F29-A4EB-AC4DCCA76BC8_1001_2">801501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1003_4">21575000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_D911327E-F16B-410C-B580-0AD0EFF60F22_1_4">98000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_7">3665000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_3">21575000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_8">85424000</us-gaap:AssetsCurrent>
  <aveo:AccruedLeaseExitChargeCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_1">6986000</aveo:AccruedLeaseExitChargeCurrent>
  <aveo:AccruedOperatingExpensesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_0">3310000</aveo:AccruedOperatingExpensesCurrent>
  <aveo:AccruedPropertyAndEquipmentCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_3">1110000</aveo:AccruedPropertyAndEquipmentCurrent>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1003_2">3000</aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1003_3">1000</aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
  <aveo:TenantImprovementAllowanceReceivableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_1_5">14900000</aveo:TenantImprovementAllowanceReceivableCurrent>
  <aveo:AccruedManufacturingAndDistributionCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_1_5">633000</aveo:AccruedManufacturingAndDistributionCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_705999x740949_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_3001_3">1000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_705999x891464_712375x891398" unitRef="iso4217_USD" decimals="-5" id="id_4941002_F9057CF0-AA7F-4E3D-9B1D-06A7F53C3C91_2001_1">200000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_708293x710575" unitRef="iso4217_USD" decimals="-5" id="id_4941002_7A2C37AC-3C20-4929-9BF8-E23D1D8DF52F_1001_0">19000000</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_708293x891906" unitRef="iso4217_USD" decimals="-5" id="id_4941002_7A2C37AC-3C20-4929-9BF8-E23D1D8DF52F_2001_1">11800000</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x711371" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1002_1">4500000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x711371_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1002_1">4500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x711371_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1002_4">4500000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1001_1">4436000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1001_1">17073000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1001_4">17075000</us-gaap:AvailableForSaleSecurities>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1001_2">3000</aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1001_3">1000</aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
  <aveo:DebtInstrumentCovenantRequiredNetAssets contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_711502x711169" unitRef="iso4217_USD" decimals="-5" id="id_4941002_9E27D0DB-DF2D-4F10-9F76-860640E633C8_2001_2">10000000</aveo:DebtInstrumentCovenantRequiredNetAssets>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-3" id="id_4941002_3427E53E-C979-4A79-BD09-334D254A8F57_1001_4">14632000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923_715990x716298" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_4001_7">7600000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923_715990x813034" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_5001_6">7000000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:RestructuringReserve contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x717013" unitRef="iso4217_USD" decimals="-3" id="id_4941002_8C981AF1-CD76-45C3-A6C5-2A7395CB949A_3001_4">34000</us-gaap:RestructuringReserve>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2004_1">30767000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2004_2">21575000</us-gaap:AvailableForSaleSecurities>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2004_3">52342000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2001_1">19012000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2001_3">19012000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2002_1">11755000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2002_2">21575000</us-gaap:AvailableForSaleSecurities>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_2002_3">33330000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x708980" unitRef="iso4217_USD" decimals="-5" id="id_4941002_BFA44916-6342-4664-8B04-FB622A6107BE_2001_0">3700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x716908" unitRef="shares" decimals="INF" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_3001_400007">535800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_3001_7">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x716908" unitRef="iso4217_USD" decimals="-5" id="id_4941002_112F8990-910F-4750-ADAB-24DB82965206_2001_0">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:LoansPayableFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_715757x707855" unitRef="iso4217_USD" decimals="-5" id="id_4941002_A1865612-6067-49F7-AB43-9CC31EA3FAB1_1001_0">14100000</us-gaap:LoansPayableFairValueDisclosure>
  <us-gaap:AssetsNet contextRef="eol_PE672770--1410-Q0005_STD_0_20140630_0_716469x705598" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CBF4B7EC-BCAE-46D9-B4AA-9C8AF4E78265_1001_1">1100000</us-gaap:AssetsNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2001_33">76134000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_35">51809000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" xsi:nil="true" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_31" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_1001_2">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_1001_400002">4296694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_28">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" xsi:nil="true" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_30" />
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_34">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_33">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_29">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_36">51809000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_23">17098000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_21">31408000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_38">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_2">2027000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_7">1252000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_37">497177000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_15">4238000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_4">811000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_22">8822000</us-gaap:LongTermLoansPayable>
  <us-gaap:StockholdersEquity contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_40">69938000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_39">-427289000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_18">1294000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_17">10383000</us-gaap:LoansPayableCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_27">0</us-gaap:PreferredStockValue>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_6">587000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_16">13263000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_19">1238000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_24">19080000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_32">52000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_20">992000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_41">146346000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_10">290000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_6">598000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1007_1">67682000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_11">2997000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_4">984000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1007_1">45630000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_9">14140000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_12">146346000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_3001_33">50826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1007_4">67680000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_7">2998000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_3">67680000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_8">128919000</us-gaap:AssetsCurrent>
  <aveo:AccruedOperatingExpensesCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_0">5319000</aveo:AccruedOperatingExpensesCurrent>
  <aveo:AccruedPropertyAndEquipmentCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_3">1905000</aveo:AccruedPropertyAndEquipmentCurrent>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1007_2">4000</aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1007_3">6000</aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
  <aveo:TenantImprovementAllowanceReceivableCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_1D8E80CA-D492-42F9-B38B-6AB3974AC0F6_2_5">5833000</aveo:TenantImprovementAllowanceReceivableCurrent>
  <aveo:AccruedManufacturingAndDistributionCurrent contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_C5F2964B-617D-4E5B-AA59-C5F10AA18CBD_2_5">1362000</aveo:AccruedManufacturingAndDistributionCurrent>
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_708293x710575" unitRef="iso4217_USD" decimals="-5" id="id_4941002_7A2C37AC-3C20-4929-9BF8-E23D1D8DF52F_1002_0">29900000</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_708293x891906" unitRef="iso4217_USD" decimals="-5" id="id_4941002_7A2C37AC-3C20-4929-9BF8-E23D1D8DF52F_2002_1">15900000</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1006_1">8005000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1006_1">8007000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1006_4">8005000</us-gaap:AvailableForSaleSecurities>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1006_3">2000</aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711515" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1005_1">7519000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_4941002_36EB64FE-C07F-4EC0-897A-8368664DDE70_1004_1">30106000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1004_1">52156000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1004_4">52156000</us-gaap:AvailableForSaleSecurities>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1004_2">4000</aveo:AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments>
  <aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1004_3">4000</aveo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712989_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1005_1">7519000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712989_712857x779597" unitRef="iso4217_USD" decimals="-3" id="id_4941002_CB10E57B-304E-49FA-805C-FDA42BE7CA04_1005_4">7519000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:RestructuringReserve contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_711976x717013" unitRef="iso4217_USD" decimals="-3" id="id_4941002_8C981AF1-CD76-45C3-A6C5-2A7395CB949A_1001_1">587000</us-gaap:RestructuringReserve>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1004_4">45823000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1004_5">67680000</us-gaap:AvailableForSaleSecurities>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1004_6">113503000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1001_4">29865000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1001_6">29865000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1002_4">15958000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1002_5">67680000</us-gaap:AvailableForSaleSecurities>
  <aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_4941002_A1BB5A77-023C-459C-AFAB-1922C0803A33_1002_6">83638000</aveo:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_713115x716908" unitRef="shares" decimals="INF" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_1001_400002">241500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_0_20131231_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_1001_2">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE672770--1410-Q0005_STD_1_20100528_0" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_2_5">2015-09-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum contextRef="eol_PE672770--1410-Q0005_STD_1_20100528_0" unitRef="pure" decimals="INF" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_2_4">0.150</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE672770--1410-Q0005_STD_1_20100528_0" id="id_4941002_98B40D61-23C8-4DD9-8DE0-7F28FBD1506A_2_0">Per annum interest is payable on the principal balance of the loan at the  greater of 11.9% and an amount equal to 11.9% plus the prime rate of interest  minus 4.75%,</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE672770--1410-Q0005_STD_1_20100528_0" id="id_4941002_EA69E0BE-387B-4848-A2B6-D8F1E1C0F289_3_2">2011-04-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE672770--1410-Q0005_STD_1_20100528_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_1_1">200000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE672770--1410-Q0005_STD_1_20120331_0" id="id_4941002_EA69E0BE-387B-4848-A2B6-D8F1E1C0F289_4_2">2013-04-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE672770--1410-Q0005_STD_1_20100602_0" unitRef="pure" decimals="INF" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2_9">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_1_20100602_0" unitRef="pure" decimals="4" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_3_6">0.6412</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_1_20100602_0" unitRef="pure" decimals="4" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_3_8">0.0281</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE672770--1410-Q0005_STD_1_20100602_0" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2_7">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <aveo:ClassOfWarrantOrRightTerm contextRef="eol_PE672770--1410-Q0005_STD_1_20100602_0" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_2_4">P7Y</aveo:ClassOfWarrantOrRightTerm>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_20">-53476000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="pure" xsi:nil="true" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2_6" />
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_13">-1.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="shares" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_14">50351000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_22">1975000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_4_2">-42000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_29">2294000</us-gaap:RepaymentsOfDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_10">76000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_5">-77000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_23">146062000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_8">-152000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestPaid contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_36">1570000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_10">-12752000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_0">647000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_12">-748000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_4_4">-66014000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_13">9000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_7">-156000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_6">-64227000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnSaleOfSecuritiesNet contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_4_2">0</us-gaap:GainLossOnSaleOfSecuritiesNet>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_14">-42000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_11">-1771000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_12">-65998000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_8">-674000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_4_3">26000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_30">51709000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_3">19773000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_6">1978000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_4">1871000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_31">-42338000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_19">4391000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_25">-40571000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:OperatingExpenses contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_5">64874000</us-gaap:OperatingExpenses>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_32">26000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_17">-647000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_16">-5637000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_9">1695000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_15">-3398000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_27">53638000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_28">365000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_3">65000</us-gaap:AssetImpairmentCharges>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_4">7936000</us-gaap:RestructuringCharges>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_24">107466000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_4_2">37165000</us-gaap:ResearchAndDevelopmentExpense>
  <aveo:IncreaseDecreaseInTenantImprovementAllowanceReceivableCurrent contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_2_11">541000</aveo:IncreaseDecreaseInTenantImprovementAllowanceReceivableCurrent>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712080x707836_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_1004_1">2300000</aveo:DecreaseInExpenseDuringThePeriod>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712080x713040_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_2004_0">12700000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2004_4">200000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_53C780B7-7A9E-4AB2-9706-AF3AF4EC597C_1004_0">26500000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_E9447C42-D6AF-4909-BFD0-FE0411782CD7_1004_0">400000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1002_4">0.0101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1002_0">0.6422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x711169" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1002_2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2002_5">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2002_1">0.7265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x716112" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2002_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_712080x707836_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_1004_1">831000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_712080x713040_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_2004_0">1147000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_713115x708980" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_E9FB46F7-9DF0-4A76-B974-C0B591DFF7B4_1004_0">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20130630_0_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_4_2">1978000</us-gaap:ShareBasedCompensation>
  <dei:TradingSymbol contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_1_0">AVEO</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_1_1">AVEO PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_321C04EE-684E-43B2-BDC1-9A03D1CF06DF_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_1_4">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_321C04EE-684E-43B2-BDC1-9A03D1CF06DF_1_3">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_321C04EE-684E-43B2-BDC1-9A03D1CF06DF_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_321C04EE-684E-43B2-BDC1-9A03D1CF06DF_1_2">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_1_2">0001325879</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A3DBC9B6-4B24-4551-BDFB-EE4F086756C7_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_321C04EE-684E-43B2-BDC1-9A03D1CF06DF_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_5001_5">7.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:BasisOfAccounting contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_AE5286C2-0922-4891-8062-4D4F70526AEF_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;(2) Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 These condensed consolidated financial statements include the
 accounts of the Company and its wholly-owned subsidiaries, AVEO
 Pharma Limited and AVEO Securities Corporation. The Company has
 eliminated all significant intercompany accounts and transactions
 in consolidation.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The accompanying condensed consolidated financial statements have
 been prepared in accordance with generally accepted accounting
 principles for interim financial information and with the
 instructions to Form&amp;#xA0;10-Q and Article&amp;#xA0;10 of Regulation
 S-X. Accordingly, they do not include all of the information and
 footnotes required by generally accepted accounting principles for
 complete financial statements. In the opinion of management, all
 adjustments, consisting of normal recurring accruals and revisions
 of estimates, considered necessary for a fair presentation of the
 condensed consolidated financial statements have been included.
 Interim results for the three and six months ended June&amp;#xA0;30,
 2014 are not necessarily indicative of the results that may be
 expected for the fiscal year ending December&amp;#xA0;31, 2014 or any
 other future period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The information presented in the condensed consolidated financial
 statements and related footnotes at June&amp;#xA0;30, 2014, and for the
 three and six months ended June&amp;#xA0;30, 2014 and 2013, is
 unaudited and the condensed consolidated balance sheet amounts and
 related footnotes at December&amp;#xA0;31, 2013 have been derived from
 the Company&amp;#x2019;s audited financial statements. For further
 information, refer to the consolidated financial statements and
 accompanying footnotes included in the Company&amp;#x2019;s annual
 report on Form 10-K for the fiscal year ended December&amp;#xA0;31,
 2013, which was filed with the U.S. Securities and Exchange
 Commission (&amp;#x201C;SEC&amp;#x201D;) on March&amp;#xA0;13, 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:NatureOfOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_00B0C45D-4CA4-4CE7-B1CB-CB568BF0BC01_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;(1) Organization&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 AVEO Pharmaceuticals, Inc. (the &amp;#x201C;Company&amp;#x201D;) is a
 biopharmaceutical company committed to discovering and developing
 targeted therapies designed to provide substantial impact in the
 lives of people with cancer by addressing unmet medical needs. The
 Company&amp;#x2019;s proprietary Human Response Platform&amp;#x2122; provides
 the Company with unique insights into cancer biology and is
 leveraged in the discovery and clinical development of
 therapeutics.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has a pipeline of monoclonal antibodies, including&lt;/p&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="4%" valign="top" align="left"&gt;(i)&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;AV-380, a potent humanized IgG1
 inhibitory monoclonal antibody targeting growth differentiating
 factor-15, or GDF15, a divergent member of the TGF-&amp;#xDF; family,
 for the potential treatment or prevention of cachexia. In 2012, the
 Company initiated a program focusing on cachexia, a serious and
 common complication of advanced cancer and a number of chronic
 diseases including chronic kidney disease, congestive heart failure
 and chronic obstructive pulmonary disease. Cachexia is
 characterized by symptoms of unintentional weight loss, progressive
 muscle wasting, and a loss of appetite. The program&amp;#x2019;s primary
 research focus is in the area of cancer cachexia, where there is a
 major unmet need,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="4%" valign="top" align="left"&gt;(ii)&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;ficlatuzumab, a potent anti-HFG
 antibody that inhibits the activity of the HGF/c-Met pathway for
 which the Company has completed a phase 2 clinical study, and has
 entered into a partnership with Biodesix, Inc.
 (&amp;#x201C;Biodesix&amp;#x201D;) to advance clinical development, and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="4%" valign="top" align="left"&gt;(iii)&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;AV-203, a potent, high affinity
 inhibitor of ErbB3 function that has demonstrated anti-tumor
 activity in multiple preclinical models for which the Company has
 completed a phase 1 dose escalation study.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company and Astellas Pharma, Inc. (&amp;#x201C;Astellas&amp;#x201D;) were
 developing tivozanib for the treatment of various types of cancers
 such as renal cell carcinoma, colorectal cancer and breast cancer
 pursuant to a worldwide collaboration and license agreement.
 Astellas notified the Company in February 2014 that it had elected
 to terminate the license agreement. This termination will become
 effective on August&amp;#xA0;11, 2014, at which time the tivozanib
 rights will be returned to the Company.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As used throughout these condensed consolidated financial
 statements, the terms &amp;#x201C;AVEO,&amp;#x201D; and the
 &amp;#x201C;Company&amp;#x201D; refer to the business of AVEO
 Pharmaceuticals, Inc. and its subsidiaries, AVEO Pharma Limited and
 AVEO Securities Corporation, both of which are wholly-owned.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has an accumulated deficit as of June&amp;#xA0;30, 2014 of
 approximately $451.7&amp;#xA0;million, and will require substantial
 additional capital for research and product development.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_3BAEB834-EF0D-4F20-8401-E75106729613_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would have been anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_75DE15B7-671F-4253-BC46-8324E45EF07A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Marketable securities in an unrealized loss position at
 June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013 consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,436&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government agency securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_1EA4866F-73E3-4567-AFFE-59B6C8E428B3_2001_2">P7Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_09DFDC89-0B50-40FA-BFDD-1DE9D5655847_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;(6) Loans Payable&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On May&amp;#xA0;28, 2010, the Company entered into a loan and security
 agreement (the &amp;#x201C;Loan Agreement&amp;#x201D;) with Hercules
 Technology II, L.P. and Hercules Technology III, L.P., affiliates
 of Hercules Technology Growth (collectively,
 &amp;#x201C;Hercules&amp;#x201D;), pursuant to which the Company received a
 loan in the aggregate principal amount of $25.0 million. The
 Company was initially required to repay the aggregate principal
 balance under the Loan Agreement in 30 equal monthly installments
 of principal starting on April&amp;#xA0;1, 2011. However, the Loan
 Agreement provided that such date would be extended under certain
 circumstances. During 2011, the Company triggered two possible
 extensions to the date from which principal payments were to be
 made and, as a result, the initial date for principal repayment was
 extended to January&amp;#xA0;1, 2012. On March&amp;#xA0;31, 2012, the
 Company entered into an amendment to the Loan Agreement, pursuant
 to which the Company increased the principal amount under the Loan
 Agreement to $26.5 million. Under the amendment to the Loan
 Agreement, the date on which the Company was required to begin
 repaying the aggregate principal balance was extended to
 April&amp;#xA0;1, 2013, at which point the Company began repaying such
 balance in 30 equal monthly installments. The Company accounted for
 this amendment as a loan modification in accordance with ASC
 470-50, &lt;i&gt;Debt&amp;#x2014;Modifications and Extinguishments.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Per annum interest is payable on the principal balance of the loan
 at the greater of 11.9% and an amount equal to 11.9% plus the prime
 rate of interest minus 4.75%, provided however, that the per annum
 interest shall not exceed 15.0%. The Company must make interest
 payments on the loan each month following the date of borrowing
 under the Loan Agreement.&amp;#xA0;The unpaid principal balance and all
 accrued but unpaid interest will be due and payable on
 September&amp;#xA0;1, 2015. The loan is secured by a lien on all of the
 Company&amp;#x2019;s personal property as of, or acquired after, the
 date of the Loan Agreement, except for intellectual property.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Loan Agreement required a deferred charge of $1.3 million which
 was paid in May 2012 related to the amendment of the Loan
 Agreement. The Loan Agreement also included an additional deferred
 charge of $1.2&amp;#xA0;million which was paid in June 2014, and is
 recorded as a loan discount and is being amortized to interest
 expense over the term of the Loan Agreement using the effective
 interest rate method. The Company had recorded a liability for the
 full amount of the charge since the payment of such amount was not
 contingent on any future event. The Company incurred approximately
 $0.2 million in loan issuance costs paid directly to the lenders
 under the Loan Agreement, which were offset against the loan
 proceeds and are accounted for as a loan discount. As part of the
 Loan Agreement, the Company issued warrants to the lenders on
 June&amp;#xA0;2, 2010 to purchase up to 156,641 shares of the
 Company&amp;#x2019;s common stock at an exercise price equal to $7.98
 per share. The Company recorded the relative fair value of the
 warrants of approximately $0.8 million as stockholders&amp;#x2019;
 equity and as a discount to the related loan outstanding and is
 amortizing the value of the discount to interest expense over the
 term of the loan using the effective interest method. The relative
 fair value of the warrants was calculated using the Black-Scholes
 option-pricing model with the following assumptions: volatility of
 64.12%, an expected term equal to the contractual life of the
 warrant (seven years), a risk-free interest rate of 2.81% and no
 dividend yield. The resulting effective interest rate for the loans
 outstanding under the Loan Agreement is approximately 13.1%.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Hercules also received an option, subject to the Company&amp;#x2019;s
 written consent, not to be unreasonably withheld, to purchase,
 either with cash or through conversion of outstanding principal
 under the loan, up to $2.0 million of equity of the Company sold in
 any sale by the Company to third parties of equity securities
 resulting in at least $10.0 million in net cash proceeds to the
 Company, subject to certain exceptions. The Company has evaluated
 the embedded conversion option, and has concluded that it does not
 need to be bifurcated and separately accounted for. No amount will
 be recognized for the conversion feature until such time as the
 conversion feature is exercised and it can be determined whether a
 beneficial conversion feature exists. As of June&amp;#xA0;30, 2014, the
 principal balance outstanding was $14.3 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Loan Agreement defines events of default, including the
 occurrence of an event that results in a material adverse effect
 upon the Company&amp;#x2019;s business operations, properties, assets or
 condition (financial or otherwise), its ability to perform its
 obligations under and in accordance with the terms of the Loan
 Agreement, or upon the ability of the lenders to enforce any of
 their rights or remedies with respect to such obligations, or upon
 the collateral under the Loan Agreement, the related liens or the
 priority thereof. As of June&amp;#xA0;30, 2014, the lenders have not
 asserted any events of default under the loan. While the Company
 does not believe that there has been a material adverse change, as
 defined in the Loan Agreement, it is possible that Hercules could
 take the position that the adverse outcome relating to the
 development and commercialization of tivozanib for RCC, including
 the FDA informing the Company that it would not approve the NDA for
 tivozanib for the treatment of patients with advanced RCC and the
 related shareholder litigation described below in footnote 10
 &amp;#x2014;Legal Proceedings, and Astellas&amp;#x2019; decision to terminate
 its collaboration with the Company, collectively constitutes a
 material adverse change, and, accordingly, an event of default,
 which could trigger a repayment of all principal and interest due
 under the loan unless such event of default is waived by Hercules.
 The Company has classified the principal amount of the loan as
 current and non-current on its consolidated balance sheet based
 upon the expected timing of the remaining payments.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Future minimum payments under the loans payable outstanding as of
 June&amp;#xA0;30, 2014 are as follows (amounts in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:96.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td colspan="2" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2014 (6 months remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,155&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,464&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less amount representing interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,182&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,096&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Loans payable, net of current portion and discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,088&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_E86A5E28-ED76-4804-BAF2-4EE8ECDD2B85_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all events or transactions that occurred
 after June&amp;#xA0;30, 2014 through the date the Company issued these
 financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_5001_400003">2962100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_E20B5807-B9ED-4DB6-B388-8A901888B9D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s revenues are generated primarily through
 collaborative research, development and commercialization
 agreements. The terms of these agreements generally contain
 multiple elements, or deliverables, which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technology, (ii)&amp;#xA0;research and development
 activities to be performed on behalf of the collaborative partner,
 and (iii)&amp;#xA0;in certain cases, services in connection with the
 manufacturing of pre-clinical and clinical material. Payments to
 the Company under these arrangements typically include one or more
 of the following: non-refundable, up-front license fees; option
 exercise fees; funding of research and/or development efforts;
 milestone payments; and royalties on future product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 When evaluating multiple element arrangements, the Company
 considers whether the deliverables under the arrangement represent
 separate units of accounting. This evaluation requires subjective
 determinations and requires management to make judgments about the
 individual deliverables and whether such deliverables are separable
 from the other aspects of the contractual relationship. In
 determining the units of accounting, management evaluates certain
 criteria, including whether the deliverables have standalone value,
 based on the relevant facts and circumstances for each arrangement.
 The consideration received is allocated among the separate units of
 accounting using the relative selling price method, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determines the estimated selling price for deliverables
 within each agreement using vendor-specific objective evidence
 (&amp;#x201C;VSOE&amp;#x201D;) of selling price, if available, third-party
 evidence (&amp;#x201C;TPE&amp;#x201D;) of selling price if VSOE is not
 available, or best estimate of selling price if neither VSOE nor
 TPE is available. Determining the best estimate of selling price
 for a deliverable requires significant judgment. The Company
 typically uses best estimate of selling price to estimate the
 selling price for licenses to the Company&amp;#x2019;s proprietary
 technology, since the Company often does not have VSOE or TPE of
 selling price for these deliverables. In those circumstances where
 the Company utilizes best estimate of selling price to determine
 the estimated selling price of a license to the Company&amp;#x2019;s
 proprietary technology, the Company considers market conditions as
 well as entity-specific factors, including those factors
 contemplated in negotiating the agreements and internally developed
 models that include assumptions related to the market opportunity,
 estimated development costs, probability of success and the time
 needed to commercialize a product candidate pursuant to the
 license. In validating the Company&amp;#x2019;s best estimate of selling
 price, the Company evaluates whether changes in the key assumptions
 used to determine the best estimate of selling price will have a
 significant effect on the allocation of arrangement consideration
 among multiple deliverables.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically receives non-refundable, up-front payments
 when licensing its intellectual property in conjunction with a
 research and development agreement. When management believes the
 license to its intellectual property does not have stand-alone
 value from the other deliverables to be provided in the
 arrangement, the Company generally recognizes revenue attributed to
 the license on a straight-line basis over the Company&amp;#x2019;s
 contractual or estimated performance period, which is typically the
 term of the Company&amp;#x2019;s research and development obligations.
 If management cannot reasonably estimate when the Company&amp;#x2019;s
 performance obligation ends, then revenue is deferred until
 management can reasonably estimate when the performance obligation
 ends. When management believes the license to its intellectual
 property has stand-alone value, the Company generally recognizes
 revenue attributed to the license upon delivery. The periods over
 which revenue should be recognized are subject to estimates by
 management and may change over the course of the research and
 development agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Payments or reimbursements resulting from the Company&amp;#x2019;s
 research and development efforts for those arrangements where such
 efforts are considered as deliverables are recognized as the
 services are performed and are presented on a gross basis so long
 as there is persuasive evidence of an arrangement, the fee is fixed
 or determinable, and collection of the related receivable is
 reasonably assured. Amounts received prior to satisfying the above
 revenue recognition criteria are recorded as deferred revenue in
 the accompanying balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance, and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company aggregates its milestones into four categories:
 (i)&amp;#xA0;clinical and development milestones, (ii)&amp;#xA0;regulatory
 milestones, (iii)&amp;#xA0;commercial milestones, and
 (iv)&amp;#xA0;patent-related milestones. Clinical and development
 milestones are typically achieved when a product candidate advances
 into a defined phase of clinical research or completes such phase.
 For example, a milestone payment may be due to the Company upon the
 initiation of a phase 3 clinical trial for a new indication, which
 is the last phase of clinical development and could eventually
 contribute to marketing approval by the U.S. Food and Drug
 Administration (&amp;#x201C;FDA&amp;#x201D;) or other global regulatory
 authorities. Regulatory milestones are typically achieved upon
 acceptance of the submission for marketing approval of a product
 candidate or upon approval to market the product candidate by the
 FDA or other global regulatory authorities. For example, a
 milestone payment may be due to the Company upon the FDA&amp;#x2019;s
 acceptance of a New Drug Application (&amp;#x201C;NDA&amp;#x201D;).
 Commercial milestones are typically achieved when an approved
 pharmaceutical product reaches certain defined levels of net sales
 by the licensee, such as when a product first achieves global sales
 or annual sales of a specified amount. Patent-related milestones
 are typically achieved when a patent application is filed or a
 patent is issued with respect to certain intellectual property
 related to the applicable collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues from clinical and development, regulatory, and
 patent-related milestone payments, if the milestones are deemed
 substantive and the milestone payments are nonrefundable, are
 recognized upon successful accomplishment of the milestones. The
 Company has concluded that the clinical and development, regulatory
 and patent-related milestones pursuant to its current research and
 development arrangements are substantive. Milestones that are not
 considered substantive are accounted for as license payments and
 recognized on a straight-line basis over the remaining period of
 performance. Revenues from commercial milestone payments are
 accounted for as royalties and are recorded as revenue upon
 achievement of the milestone, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_75D89719-273C-4660-97D6-D4F082423251_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of the status of the Company&amp;#x2019;s stock option
 activity at June&amp;#xA0;30, 2014 and changes during the six months
 then ended is presented in the table and narrative below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,296,694&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,962,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,015,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.16&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;801,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,416,319&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;204,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,401,542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155,461&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_5001_3">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_20">-35220000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_8DBDCCC9-6120-450D-BCBE-EFBAD6FB68E1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company provides for income taxes using the asset-liability
 method. Under this method, deferred tax assets and liabilities are
 recognized based on differences between financial reporting and tax
 bases of assets and liabilities, and are measured using the enacted
 tax rates and laws that will be in effect when the differences are
 expected to reverse. Uncertain tax positions are recognized if the
 position is more-likely-than-not to be sustained upon examination
 by a tax authority. Unrecognized tax benefits represent tax
 positions for which reserves have been established. The Company
 maintains a full valuation allowance on all deferred tax
 assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_3EDCE379-E163-4BE1-AFCB-B6DBEFD66D96_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables summarize the cash equivalents and marketable
 securities measured at fair value on a recurring basis in the
 accompanying consolidated balance sheets as of June&amp;#xA0;30, 2014
 and December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,767&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,503&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_1029E59F-16A9-4E40-B935-EFF3C66500BF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of the
 Company&amp;#x2019;s restructuring activity recorded in operating
 expenses and in current liabilities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amounts&amp;#xA0;accrued&amp;#xA0;at&lt;br /&gt;
 December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 amounts&lt;br /&gt;
 paid&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 amounts&lt;br /&gt;
 accrued at&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee severance, benefits and related costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(553&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_5A4245A0-B1A3-436D-8062-F5812E8026A1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses consisted of the following as of June&amp;#xA0;30,
 2014 and December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,319&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Facility lease exit costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Salaries and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;485&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Manufacturing and distribution&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restructuring&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_252D932A-50FC-40E3-BE92-7B8EFB0B17F4_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Future minimum payments under the loans payable outstanding as of
 June&amp;#xA0;30, 2014 are as follows (amounts in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:96.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td colspan="2" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2014 (6 months remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,155&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,464&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less amount representing interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,182&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,096&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Loans payable, net of current portion and discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,088&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_4462644C-2D96-4595-8B02-80BFCE2E2BAA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(5) Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses consisted of the following as of June&amp;#xA0;30,
 2014 and December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,319&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Facility lease exit costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Salaries and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;485&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Manufacturing and distribution&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restructuring&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_1CF0DED5-12AD-4500-9BEB-32EC4F4892E9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(8) Strategic Restructuring&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In connection with the receipt of a Complete Response Letter from
 the FDA informing the Company that the FDA would not approve the
 Company&amp;#x2019;s NDA for tivozanib for the treatment of patients
 with advanced RCC, the Company announced a strategic restructuring
 in June 2013 to refocus the Company&amp;#x2019;s efforts on the then
 on-going clinical development of tivozanib in colorectal and breast
 cancer and on the advancement of key pipeline and preclinical
 assets. As part of this restructuring, the Company decided not to
 pursue the development of tivozanib in RCC. This restructuring was
 completed as of December&amp;#xA0;31, 2013 and resulted in costs
 totaling $8.0 million, which includes impairment charges of
 $0.3&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of the
 Company&amp;#x2019;s restructuring activity recorded in operating
 expenses and in current liabilities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amounts&amp;#xA0;accrued&amp;#xA0;at&lt;br /&gt;
 December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 amounts&lt;br /&gt;
 paid&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Restructuring&lt;br /&gt;
 amounts&lt;br /&gt;
 accrued at&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee severance, benefits and related costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(553&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 All remaining accrued amounts are current and are reflected within
 accrued expenses on the consolidated balance sheet.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:MarketableSecuritiesPolicy contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_EA0D93C2-A955-47C8-9F1E-4259416C87EF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Marketable securities at June&amp;#xA0;30, 2014 consisted of
 asset-backed securities and corporate debt securities, including
 commercial paper, maintained by an investment manager. Marketable
 securities at December&amp;#xA0;31, 2013 consisted of municipal bonds,
 asset-backed securities, and corporate debt securities, including
 commercial paper, maintained by an investment manager. Credit risk
 is reduced as a result of the Company&amp;#x2019;s policy to limit the
 amount invested in any one issue. Marketable securities consist
 primarily of investments which have expected average maturity dates
 in excess of three months, but not longer than 24 months. The
 Company classifies these investments as available-for-sale.
 Unrealized gains and losses are included in other comprehensive
 (loss) income until realized. The cost of securities sold is based
 on the specific identification method. There were no realized gains
 or losses recognized on the sale or maturity of securities during
 the three and six months ended June&amp;#xA0;30, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Available-for-sale securities at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,075&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,573&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Municipal bonds (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,007&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,682&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The aggregate fair value of securities in an unrealized loss
 position for less than 12 months at June&amp;#xA0;30, 2014 was $8.9
 million, representing five securities. There were no securities
 that were in an unrealized loss position for greater than 12 months
 at June&amp;#xA0;30, 2014. The unrealized loss was caused by a
 temporary change in the market for those securities primarily
 caused by changes in market interest rates. There was no change in
 the credit risk of the securities. To determine whether an
 other-than-temporary impairment exists, the Company performs an
 analysis to assess whether it intends to sell, or whether it would
 more likely than not be required to sell, the security before the
 expected recovery of the amortized cost basis. Where the Company
 intends to sell a security, or may be required to do so, the
 security&amp;#x2019;s decline in fair value is deemed to be
 other-than-temporary and the full amount of the unrealized loss is
 recorded in the statement of operations as an other-than-temporary
 impairment charge. When this is not the case, the Company performs
 additional analyses on all securities with unrealized losses to
 evaluate losses associated with the creditworthiness of the
 security. Credit losses are identified where the Company does not
 expect to receive cash flows, based on using a single best
 estimate, sufficient to recover the amortized cost basis of a
 security and these are recognized in other income (expense), net.
 The Company does not believe an other-than-temporary impairment
 exists with respect to those securities in an unrealized loss
 position at June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Marketable securities in an unrealized loss position at
 June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013 consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,436&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government agency securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_EA78BE7B-8C2A-42C3-BCD0-712F9161796C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost and are depreciated using
 the straight-line method over the estimated useful lives of the
 respective assets. Maintenance and repair costs are charged to
 expense as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="pure" xsi:nil="true" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1_6" />
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_CA222634-652F-47A9-A2A5-F32B836DD538_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers highly liquid investments with a maturity of
 three months or less when purchased to be cash equivalents. Cash
 equivalents at June&amp;#xA0;30, 2014 consisted of money market funds
 and corporate debt securities, including commercial paper,
 maintained by an investment manager totaling $19.0 million and
 $11.8 million, respectively. Cash equivalents at December&amp;#xA0;31,
 2013 consisted of money market funds and corporate debt securities,
 including commercial paper, maintained by an investment manager
 totaling $29.9 million and $15.9 million, respectively. The
 carrying values of our cash equivalent securities approximate fair
 value due to their short term maturities.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_859AFD85-5DBC-4C1E-BC92-5F743831E7C2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(10) Legal Proceedings&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Two class action lawsuits have been filed against the Company and
 certain present and former officers and members of the
 Company&amp;#x2019;s board of directors, (Tuan Ha-Ngoc, David N.
 Johnston, William Slichenmyer and Ronald DePinho), in the United
 States District Court for the District of Massachusetts, one
 captioned Paul Sanders v. Aveo Pharmaceuticals, Inc., et al.,
 No.&amp;#xA0;1:13-cv-11157-JLT, filed on May&amp;#xA0;9, 2013, and the
 other captioned Christine Krause v. AVEO Pharmaceuticals, Inc., et
 al., No.&amp;#xA0;1:13-cv-11320-JLT, filed on May&amp;#xA0;31, 2013. On
 December&amp;#xA0;4, 2013, the District Court consolidated the
 complaints as In re AVEO Pharmaceuticals, Inc. Securities
 Litigation et al., No.&amp;#xA0;1:13-cv-11157-DJC, and an amended
 complaint was filed on February&amp;#xA0;3, 2014. The amended complaint
 purports to be brought on behalf of shareholders who purchased the
 Company&amp;#x2019;s common stock between January&amp;#xA0;3, 2012 and
 May&amp;#xA0;1, 2013. The amended complaint generally alleges that the
 Company and certain of its present and former officers and
 directors violated Sections 10(b) and/or 20(a) of the Securities
 Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
 making allegedly false and/or misleading statements concerning the
 phase 3 trial design and results for our TIVO-1 study in an effort
 to lead investors to believe that the drug would receive approval
 from the FDA. The amended complaint seeks unspecified damages,
 interest, attorneys&amp;#x2019; fees, and other costs. On April&amp;#xA0;4,
 2014, the Company filed a motion to dismiss the consolidated class
 action complaint with prejudice. Lead plaintiffs filed an
 opposition to the motion to dismiss on June&amp;#xA0;10, 2014, and the
 Company filed a reply to the opposition on July&amp;#xA0;10, 2014. The
 Court heard oral argument on the Company&amp;#x2019;s motion to dismiss
 on July&amp;#xA0;22, 2014. The Company denies any allegations of
 wrongdoing and intends to vigorously defend against this lawsuit.
 However, there is no assurance that the Company will be successful
 in our defense or that insurance will be available or adequate to
 fund any settlement or judgment or the litigation costs of the
 action. Moreover, the Company is unable to predict the outcome or
 reasonably estimate a range of possible loss at this time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;3, 2013, the Company received a subpoena from the SEC,
 requesting documents and information concerning tivozanib,
 including related communications with the FDA, investors and
 others. The Company is fully cooperating with the SEC regarding
 this fact-finding inquiry. The SEC has informed the Company that
 this inquiry should not be construed as an indication that any
 violations of law have occurred or that the SEC has any negative
 opinion of any person, entity or security.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On April&amp;#xA0;4, 2014, Karen J. van Ingen, a purported purchaser of
 AVEO stock, filed a derivative complaint allegedly on behalf of
 AVEO in the United States District Court for the District of
 Massachusetts, Civil Action No.&amp;#xA0;1:14-cv-11672-DJC, naming
 AVEO, as a nominal defendant and also naming as defendants present
 and former members of the Company&amp;#x2019;s board of directors,
 including Tuan Ha-Ngoc, Henri A. Termeer, Kenneth M. Bate, Anthony
 B. Evnin, Robert Epstein, Raju Kucherlapati, Robert C. Young, and
 Kenneth E. Weg. The complaint alleges breach of fiduciary duty and
 abuse of control between January 2012 and May 2013 with respect to
 allegedly misleading statements and omissions regarding tivozanib.
 The complaint seeks, among other relief, unspecified damages, costs
 and expenses, including attorneys&amp;#x2019; fees, an order requiring
 the Company to implement certain corporate governance reforms,
 restitution from the defendants and such other relief as the court
 might find just and proper. On July&amp;#xA0;25, 2014, defendants filed
 a motion to dismiss the derivative complaint with prejudice. The
 Company denies any allegations of wrongdoing and intends to
 vigorously defend this lawsuit. However, there is no assurance that
 the Company will be successful in its defense or that insurance
 will be available or adequate to fund any settlement or judgment or
 the litigation costs of this action. Moreover, the Company is
 unable to predict the outcome or reasonably estimate a range of
 possible loss at this time.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_1EA4866F-73E3-4567-AFFE-59B6C8E428B3_2001_3">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="shares" xsi:nil="true" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_5001_4" />
  <us-gaap:DebtInstrumentCovenantDescription contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_9E27D0DB-DF2D-4F10-9F76-860640E633C8_2_0">Hercules also received an option, subject to the Company&apos;s written consent, not  to be unreasonably withheld, to purchase, either with cash or through conversion  of outstanding principal under the loan, up to $2.0 million of equity of the  Company sold in any sale by the Company to third parties of equity securities  resulting in at least $10.0 million in net cash proceeds to the Company, subject  to certain exceptions.</us-gaap:DebtInstrumentCovenantDescription>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_180C31E9-DF10-4480-8EC2-CDD7BFDF0EF8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 credit risk primarily consist of cash, cash equivalents and
 available-for-sale marketable securities. The Company maintains
 deposits in federally insured financial institutions in excess of
 federally insured limits.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Management believes that the Company is not exposed to significant
 credit risk due to the financial position of the depository
 institutions in which those deposits are held.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s credit risk related to marketable securities is
 reduced as a result of the Company&amp;#x2019;s policy to limit the
 amount invested in any one issue.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_8F5CAFC8-2BB3-46B8-B094-2A538740A17C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment and Geographic Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Operating segments are defined as components of an enterprise
 engaging in business activities for which discrete financial
 information is available and regularly reviewed by the chief
 operating decision maker in deciding how to allocate resources and
 in assessing performance. The Company views its operations and
 manages its business in one operating segment principally in the
 United States. As of June&amp;#xA0;30, 2014, the Company has $1.1
 million of net assets located in the United Kingdom.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_A0C671E2-A2BB-4FB0-B637-6832EB4A6108_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(3) Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s revenues are generated primarily through
 collaborative research, development and commercialization
 agreements. The terms of these agreements generally contain
 multiple elements, or deliverables, which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technology, (ii)&amp;#xA0;research and development
 activities to be performed on behalf of the collaborative partner,
 and (iii)&amp;#xA0;in certain cases, services in connection with the
 manufacturing of pre-clinical and clinical material. Payments to
 the Company under these arrangements typically include one or more
 of the following: non-refundable, up-front license fees; option
 exercise fees; funding of research and/or development efforts;
 milestone payments; and royalties on future product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 When evaluating multiple element arrangements, the Company
 considers whether the deliverables under the arrangement represent
 separate units of accounting. This evaluation requires subjective
 determinations and requires management to make judgments about the
 individual deliverables and whether such deliverables are separable
 from the other aspects of the contractual relationship. In
 determining the units of accounting, management evaluates certain
 criteria, including whether the deliverables have standalone value,
 based on the relevant facts and circumstances for each arrangement.
 The consideration received is allocated among the separate units of
 accounting using the relative selling price method, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determines the estimated selling price for deliverables
 within each agreement using vendor-specific objective evidence
 (&amp;#x201C;VSOE&amp;#x201D;) of selling price, if available, third-party
 evidence (&amp;#x201C;TPE&amp;#x201D;) of selling price if VSOE is not
 available, or best estimate of selling price if neither VSOE nor
 TPE is available. Determining the best estimate of selling price
 for a deliverable requires significant judgment. The Company
 typically uses best estimate of selling price to estimate the
 selling price for licenses to the Company&amp;#x2019;s proprietary
 technology, since the Company often does not have VSOE or TPE of
 selling price for these deliverables. In those circumstances where
 the Company utilizes best estimate of selling price to determine
 the estimated selling price of a license to the Company&amp;#x2019;s
 proprietary technology, the Company considers market conditions as
 well as entity-specific factors, including those factors
 contemplated in negotiating the agreements and internally developed
 models that include assumptions related to the market opportunity,
 estimated development costs, probability of success and the time
 needed to commercialize a product candidate pursuant to the
 license. In validating the Company&amp;#x2019;s best estimate of selling
 price, the Company evaluates whether changes in the key assumptions
 used to determine the best estimate of selling price will have a
 significant effect on the allocation of arrangement consideration
 among multiple deliverables.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically receives non-refundable, up-front payments
 when licensing its intellectual property in conjunction with a
 research and development agreement. When management believes the
 license to its intellectual property does not have stand-alone
 value from the other deliverables to be provided in the
 arrangement, the Company generally recognizes revenue attributed to
 the license on a straight-line basis over the Company&amp;#x2019;s
 contractual or estimated performance period, which is typically the
 term of the Company&amp;#x2019;s research and development obligations.
 If management cannot reasonably estimate when the Company&amp;#x2019;s
 performance obligation ends, then revenue is deferred until
 management can reasonably estimate when the performance obligation
 ends. When management believes the license to its intellectual
 property has stand-alone value, the Company generally recognizes
 revenue attributed to the license upon delivery. The periods over
 which revenue should be recognized are subject to estimates by
 management and may change over the course of the research and
 development agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Payments or reimbursements resulting from the Company&amp;#x2019;s
 research and development efforts for those arrangements where such
 efforts are considered as deliverables are recognized as the
 services are performed and are presented on a gross basis so long
 as there is persuasive evidence of an arrangement, the fee is fixed
 or determinable, and collection of the related receivable is
 reasonably assured. Amounts received prior to satisfying the above
 revenue recognition criteria are recorded as deferred revenue in
 the accompanying balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance, and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company aggregates its milestones into four categories:
 (i)&amp;#xA0;clinical and development milestones, (ii)&amp;#xA0;regulatory
 milestones, (iii)&amp;#xA0;commercial milestones, and
 (iv)&amp;#xA0;patent-related milestones. Clinical and development
 milestones are typically achieved when a product candidate advances
 into a defined phase of clinical research or completes such phase.
 For example, a milestone payment may be due to the Company upon the
 initiation of a phase 3 clinical trial for a new indication, which
 is the last phase of clinical development and could eventually
 contribute to marketing approval by the U.S. Food and Drug
 Administration (&amp;#x201C;FDA&amp;#x201D;) or other global regulatory
 authorities. Regulatory milestones are typically achieved upon
 acceptance of the submission for marketing approval of a product
 candidate or upon approval to market the product candidate by the
 FDA or other global regulatory authorities. For example, a
 milestone payment may be due to the Company upon the FDA&amp;#x2019;s
 acceptance of a New Drug Application (&amp;#x201C;NDA&amp;#x201D;).
 Commercial milestones are typically achieved when an approved
 pharmaceutical product reaches certain defined levels of net sales
 by the licensee, such as when a product first achieves global sales
 or annual sales of a specified amount. Patent-related milestones
 are typically achieved when a patent application is filed or a
 patent is issued with respect to certain intellectual property
 related to the applicable collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues from clinical and development, regulatory, and
 patent-related milestone payments, if the milestones are deemed
 substantive and the milestone payments are nonrefundable, are
 recognized upon successful accomplishment of the milestones. The
 Company has concluded that the clinical and development, regulatory
 and patent-related milestones pursuant to its current research and
 development arrangements are substantive. Milestones that are not
 considered substantive are accounted for as license payments and
 recognized on a straight-line basis over the remaining period of
 performance. Revenues from commercial milestone payments are
 accounted for as royalties and are recorded as revenue upon
 achievement of the milestone, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses are charged to expense as
 incurred. Research and development expenses consist of costs
 incurred in performing research and development activities,
 including personnel-related costs such as salaries and stock-based
 compensation, facilities, research-related overhead, clinical trial
 costs, manufacturing costs and costs of other contracted services,
 license fees, and other external costs. Nonrefundable advance
 payments for goods and services that will be used in future
 research and development activities are expensed when the activity
 has been performed or when the goods have been received.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers highly liquid investments with a maturity of
 three months or less when purchased to be cash equivalents. Cash
 equivalents at June&amp;#xA0;30, 2014 consisted of money market funds
 and corporate debt securities, including commercial paper,
 maintained by an investment manager totaling $19.0 million and
 $11.8 million, respectively. Cash equivalents at December&amp;#xA0;31,
 2013 consisted of money market funds and corporate debt securities,
 including commercial paper, maintained by an investment manager
 totaling $29.9 million and $15.9 million, respectively. The
 carrying values of our cash equivalent securities approximate fair
 value due to their short term maturities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Marketable securities at June&amp;#xA0;30, 2014 consisted of
 asset-backed securities and corporate debt securities, including
 commercial paper, maintained by an investment manager. Marketable
 securities at December&amp;#xA0;31, 2013 consisted of municipal bonds,
 asset-backed securities, and corporate debt securities, including
 commercial paper, maintained by an investment manager. Credit risk
 is reduced as a result of the Company&amp;#x2019;s policy to limit the
 amount invested in any one issue. Marketable securities consist
 primarily of investments which have expected average maturity dates
 in excess of three months, but not longer than 24 months. The
 Company classifies these investments as available-for-sale.
 Unrealized gains and losses are included in other comprehensive
 (loss) income until realized. The cost of securities sold is based
 on the specific identification method. There were no realized gains
 or losses recognized on the sale or maturity of securities during
 the three and six months ended June&amp;#xA0;30, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Available-for-sale securities at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,075&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,573&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Municipal bonds (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,007&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,682&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The aggregate fair value of securities in an unrealized loss
 position for less than 12 months at June&amp;#xA0;30, 2014 was $8.9
 million, representing five securities. There were no securities
 that were in an unrealized loss position for greater than 12 months
 at June&amp;#xA0;30, 2014. The unrealized loss was caused by a
 temporary change in the market for those securities primarily
 caused by changes in market interest rates. There was no change in
 the credit risk of the securities. To determine whether an
 other-than-temporary impairment exists, the Company performs an
 analysis to assess whether it intends to sell, or whether it would
 more likely than not be required to sell, the security before the
 expected recovery of the amortized cost basis. Where the Company
 intends to sell a security, or may be required to do so, the
 security&amp;#x2019;s decline in fair value is deemed to be
 other-than-temporary and the full amount of the unrealized loss is
 recorded in the statement of operations as an other-than-temporary
 impairment charge. When this is not the case, the Company performs
 additional analyses on all securities with unrealized losses to
 evaluate losses associated with the creditworthiness of the
 security. Credit losses are identified where the Company does not
 expect to receive cash flows, based on using a single best
 estimate, sufficient to recover the amortized cost basis of a
 security and these are recognized in other income (expense), net.
 The Company does not believe an other-than-temporary impairment
 exists with respect to those securities in an unrealized loss
 position at June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Marketable securities in an unrealized loss position at
 June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013 consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,436&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government agency securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 credit risk primarily consist of cash, cash equivalents and
 available-for-sale marketable securities. The Company maintains
 deposits in federally insured financial institutions in excess of
 federally insured limits.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Management believes that the Company is not exposed to significant
 credit risk due to the financial position of the depository
 institutions in which those deposits are held.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s credit risk related to marketable securities is
 reduced as a result of the Company&amp;#x2019;s policy to limit the
 amount invested in any one issue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company records cash equivalents and marketable securities at
 fair value. The accounting standards for fair value measurements
 establish a hierarchy that distinguishes between fair value
 measurements based on market data (observable inputs) and those
 based on the Company&amp;#x2019;s own assumptions (unobservable inputs).
 The hierarchy consists of three levels:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Quoted market prices in
 active markets for identical assets or liabilities. Assets that are
 valued utilizing only Level 1 inputs include money market
 funds.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" align="left"&gt;Level 2&amp;#x2014;Inputs other than Level 1 inputs that are
 either directly or indirectly observable, such as quoted market
 prices, interest rates and yield curves. Assets that are valued
 utilizing Level 2 inputs include U.S. government agency securities,
 asset-backed securities, and corporate bonds, including commercial
 paper. These investments have been initially valued at the
 transaction price and are subsequently valued, at the end of each
 reporting period, utilizing third party pricing services or other
 observable market data. The pricing services utilize industry
 standard valuation models, including both income and market based
 approaches and observable market inputs to determine value. These
 observable market inputs include reportable trades, benchmark
 yields, credit spreads, broker/dealer quotes, bids, offers, current
 spot rates, and other industry and economic events. The Company
 validates the prices provided by third party pricing services by
 reviewing their pricing methods and matrices, obtaining market
 values from other pricing sources, analyzing pricing data in
 certain instances and confirming that the relevant markets are
 active. After completing its validation procedures, the Company did
 not adjust or override any fair value measurements provided by
 pricing services as of June&amp;#xA0;30, 2014 or December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Unobservable inputs
 developed using estimates and assumptions developed by the Company,
 which reflect those that a market participant would use. The
 Company made one nonrecurring fair value measurement associated
 with a lease exit liability. The Company currently has no assets or
 liabilities measured at fair value on a recurring basis that
 utilize Level 3 inputs.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables summarize the cash equivalents and marketable
 securities measured at fair value on a recurring basis in the
 accompanying consolidated balance sheets as of June&amp;#xA0;30, 2014
 and December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,767&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,503&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In 2014, the Company has recorded liabilities totaling $15.2
 million associated with the exit of portions of its leased
 facilities (refer to footnote 9). The Company measured the fair
 values of the liabilities based on the present value of the
 remaining lease payments less the amount of sublease income the
 Company estimates it could reasonably obtain. The Company estimated
 its future rental and operating expense payment obligations using
 the terms of its lease agreement and its historical share of the
 building&amp;#x2019;s expenses, adjusting for the effects of inflation.
 The estimated sublease income to be received is based upon market
 rates for comparable spaces in the Cambridge area. The net cash
 outflows over the remaining life of the lease were discounted using
 a credit-risk adjusted risk-free rate. The Company has classified
 these lease liabilities as Level 3 fair value measurements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the Company&amp;#x2019;s loans payable at
 June&amp;#xA0;30, 2014, computed pursuant to a discounted cash flow
 technique using the effective interest rate under the loan, is
 $14.1 million and is considered a Level 2 fair value measurement.
 The effective interest rate, which reflects the current market
 rate, considers the fair value of the warrant issued in connection
 with the loan, loan issuance costs and the deferred charge.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Tenant Improvement Allowance Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is entitled to be reimbursed by the Company&amp;#x2019;s
 landlord for certain expenditures associated with improvements made
 to its leased facility at 650 E. Kendall Street in Cambridge,
 Massachusetts. These receivables are recorded in the period that
 the improvements are made and the reimbursement is earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost and are depreciated using
 the straight-line method over the estimated useful lives of the
 respective assets. Maintenance and repair costs are charged to
 expense as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company reviews long-lived assets, including property and
 equipment, for impairment whenever changes in business
 circumstances indicate that the carrying amount of the asset may
 not be fully recoverable. The Company recognized $5.1 million and
 $7.6&amp;#xA0;million of impairment losses for three and six months
 ended June&amp;#xA0;30, 2014, respectively, related to leasehold
 improvements (refer to Footnote&amp;#xA0;9). During the year ended
 December&amp;#xA0;31, 2013, the Company recognized $0.1 million of
 impairment losses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic (loss) earnings per share is computed by dividing net (loss)
 income available to common stockholders by the weighted-average
 number of common shares outstanding during the period. Diluted
 (loss) earnings per share is computed by dividing net (loss) income
 available to common stockholders by the weighted-average number of
 common shares and dilutive common share equivalents then
 outstanding. Potential common share equivalents consist of
 restricted stock awards and the incremental common shares issuable
 upon the exercise of stock options and warrants. Since the Company
 had a net loss for all periods presented, the effect of all
 potentially dilutive securities is anti-dilutive. Accordingly,
 basic and diluted net loss per common share is the same. Under the
 treasury stock method, unexercised &amp;#x201C;in-the-money&amp;#x201D; stock
 options are assumed to be exercised at the beginning of the period
 or at issuance, if later. The assumed proceeds are then used to
 purchase common shares at the average market price during the
 period. Stock-based payment awards that entitle their holders to
 receive non-forfeitable dividends before vesting are considered
 participating securities and are included in the calculation of
 basic and diluted earnings per share.&amp;#xA0;Common share equivalents
 have not been included in the net loss per share computation for
 the three and six months ended June&amp;#xA0;30, 2014 and June&amp;#xA0;30,
 2013 because their effect is anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would have been anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Under the Company&amp;#x2019;s stock-based compensation programs, the
 Company periodically grants stock options and restricted stock to
 employees, directors and nonemployee consultants. The Company also
 issues shares under an employee stock purchase plan. The fair value
 of all awards is recognized in the Company&amp;#x2019;s statements of
 operations over the requisite service period for each award. Awards
 that vest as the recipient provides service are expensed on a
 straight-line basis over the requisite service period. Other
 awards, such as performance-based awards that vest upon the
 achievement of specified goals, are expensed using the accelerated
 attribution method if achievement of the specified goals is
 considered probable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of equity-classified awards to employees and
 directors are measured at fair value on the date the awards are
 granted. Awards to nonemployee consultants are recorded at their
 fair values and are re-measured as of each balance sheet date until
 the recipient&amp;#x2019;s services are complete. During the three and
 six months ended June&amp;#xA0;30, 2014 and June&amp;#xA0;30, 2013, the
 Company recorded the following stock-based compensation
 expense:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;515&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(643&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;656&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense is allocated to research and
 development and general and administrative expense based upon the
 department of the employee to whom each award was granted. No
 related tax benefits of the stock-based compensation expense have
 been recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company provides for income taxes using the asset-liability
 method. Under this method, deferred tax assets and liabilities are
 recognized based on differences between financial reporting and tax
 bases of assets and liabilities, and are measured using the enacted
 tax rates and laws that will be in effect when the differences are
 expected to reverse. Uncertain tax positions are recognized if the
 position is more-likely-than-not to be sustained upon examination
 by a tax authority. Unrecognized tax benefits represent tax
 positions for which reserves have been established. The Company
 maintains a full valuation allowance on all deferred tax
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment and Geographic Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Operating segments are defined as components of an enterprise
 engaging in business activities for which discrete financial
 information is available and regularly reviewed by the chief
 operating decision maker in deciding how to allocate resources and
 in assessing performance. The Company views its operations and
 manages its business in one operating segment principally in the
 United States. As of June&amp;#xA0;30, 2014, the Company has $1.1
 million of net assets located in the United Kingdom.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with
 accounting principles generally accepted in the United States
 (&amp;#x201C;GAAP&amp;#x201D;) requires the Company&amp;#x2019;s management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For a discussion of recent accounting pronouncements adopted by the
 Company, please refer to Note 2, &amp;#x201C;Significant Accounting
 Policies,&amp;#x201D; included in the Company&amp;#x2019;s Annual Report on
 Form 10-K for the fiscal year ended December&amp;#xA0;31, 2013, filed
 with the SEC on March&amp;#xA0;13, 2014. The Company did not adopt any
 new accounting pronouncements during the three months ended
 June&amp;#xA0;30, 2014 that had a material effect on the
 Company&amp;#x2019;s condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB and the International Accounting Standards
 Board (IASB) (collectively, the &amp;#x201C;Boards&amp;#x201D;) jointly
 issued a comprehensive new revenue recognition standard that will
 supersede nearly all existing revenue recognition guidance under
 US&amp;#xA0;GAAP and IFRS. The standard is effective for public
 entities for annual and interim periods beginning after
 December&amp;#xA0;15, 2016. Early adoption is not permitted under US
 GAAP. The Company is currently evaluating what effect, if any, this
 standard will have on its revenue recognition policies and its
 financial statements, including how the standard will be
 adopted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has reclassified the tenant improvement allowance
 receivable from prepaid expenses and other current assets on the
 consolidated balance sheets at December&amp;#xA0;31, 2013 to a separate
 financial statement line to conform to the current period
 presentation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all events or transactions that occurred
 after June&amp;#xA0;30, 2014 through the date the Company issued these
 financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_0C37A97A-B051-44ED-BFF0-4FFA547F96AA_5001_400005">1015604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:UseOfEstimates contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_EC2303B2-1116-4476-8BF6-0A1F6DBA5529_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with
 accounting principles generally accepted in the United States
 (&amp;#x201C;GAAP&amp;#x201D;) requires the Company&amp;#x2019;s management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_4D5C746D-E82E-4E7C-B433-CF7C6BE601A5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic (loss) earnings per share is computed by dividing net (loss)
 income available to common stockholders by the weighted-average
 number of common shares outstanding during the period. Diluted
 (loss) earnings per share is computed by dividing net (loss) income
 available to common stockholders by the weighted-average number of
 common shares and dilutive common share equivalents then
 outstanding. Potential common share equivalents consist of
 restricted stock awards and the incremental common shares issuable
 upon the exercise of stock options and warrants. Since the Company
 had a net loss for all periods presented, the effect of all
 potentially dilutive securities is anti-dilutive. Accordingly,
 basic and diluted net loss per common share is the same. Under the
 treasury stock method, unexercised &amp;#x201C;in-the-money&amp;#x201D; stock
 options are assumed to be exercised at the beginning of the period
 or at issuance, if later. The assumed proceeds are then used to
 purchase common shares at the average market price during the
 period. Stock-based payment awards that entitle their holders to
 receive non-forfeitable dividends before vesting are considered
 participating securities and are included in the calculation of
 basic and diluted earnings per share.&amp;#xA0;Common share equivalents
 have not been included in the net loss per share computation for
 the three and six months ended June&amp;#xA0;30, 2014 and June&amp;#xA0;30,
 2013 because their effect is anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would have been anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_0D63921A-3988-41A5-84E1-09DFA4C60B8D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of stock options subject only to service or
 performance conditions that are granted to employees is estimated
 on the date of grant using the Black-Scholes option-pricing model
 using the assumptions noted in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 8pt; Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 8pt; Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;72.06-73.98%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;71.35-72.65%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.88%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.69%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;72.06%-73.98%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;64.22-72.65%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.88-2.02%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.01-1.69%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_9261A008-8D2B-4EC4-94D0-1D0F8254D9DB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The restricted stock activity for the six months ended
 June&amp;#xA0;30, 2014 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Fair-Value&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(133,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested/Released&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_13">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_008BB8E7-8B74-40E8-A919-EBB733D4FB05_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company reviews long-lived assets, including property and
 equipment, for impairment whenever changes in business
 circumstances indicate that the carrying amount of the asset may
 not be fully recoverable. The Company recognized $5.1 million and
 $7.6&amp;#xA0;million of impairment losses for three and six months
 ended June&amp;#xA0;30, 2014, respectively, related to leasehold
 improvements (refer to Footnote&amp;#xA0;9). During the year ended
 December&amp;#xA0;31, 2013, the Company recognized $0.1 million of
 impairment losses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_4941002_39811539-2CD8-4655-B7D4-50D040CBEA25_5001_4" />
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_14">51649000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_9ED15411-CACB-4307-B39F-C3FA3AFB214F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses are charged to expense as
 incurred. Research and development expenses consist of costs
 incurred in performing research and development activities,
 including personnel-related costs such as salaries and stock-based
 compensation, facilities, research-related overhead, clinical trial
 costs, manufacturing costs and costs of other contracted services,
 license fees, and other external costs. Nonrefundable advance
 payments for goods and services that will be used in future
 research and development activities are expensed when the activity
 has been performed or when the goods have been received.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_EA69E0BE-387B-4848-A2B6-D8F1E1C0F289_1_1">30 equal monthly installments</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_1EA4866F-73E3-4567-AFFE-59B6C8E428B3_2001_4">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_CD2D2955-576B-4294-AC0D-2448D7489E76_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(7) Stock-based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company issued stock options and restricted stock awards during
 the three months ended June&amp;#xA0;30, 2014. In June 2014, the
 Company issued stock options to purchase 2,250,000 shares of common
 stock which contained market performance conditions which were not
 deemed probable of vesting at June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of the status of the Company&amp;#x2019;s stock option
 activity at June&amp;#xA0;30, 2014 and changes during the six months
 then ended is presented in the table and narrative below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,296,694&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,962,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,015,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.16&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,243,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;801,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,416,319&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;204,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,401,542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155,461&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of stock options subject only to service or
 performance conditions that are granted to employees is estimated
 on the date of grant using the Black-Scholes option-pricing model
 using the assumptions noted in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 8pt; Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 8pt; Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;72.06-73.98%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;71.35-72.65%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.88%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.69%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;72.06%-73.98%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;64.22-72.65%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.50-6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.88-2.02%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.01-1.69%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The risk-free interest rate is determined based upon the United
 States Treasury&amp;#x2019;s rates for U.S. Treasury zero-coupon bonds
 with maturities similar to those of the expected term of the
 options being valued. The Company does not expect to pay dividends
 in the foreseeable future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company does not have sufficient history to support a
 calculation of volatility and expected term using only its
 historical data. As such, the Company has used a weighted-average
 volatility considering the Company&amp;#x2019;s own volatility since
 March 2010, and the volatilities of several peer companies. For
 purposes of identifying similar entities, the Company considered
 characteristics such as industry, length of trading history,
 similar vesting terms and in-the-money option status. Due to lack
 of available option activity data, the Company elected to use the
 &amp;#x201C;simplified&amp;#x201D; method for &amp;#x201C;plain vanilla&amp;#x201D;
 options to estimate the expected term of the stock option grants.
 Under this approach, the weighted-average expected life is presumed
 to be the average of the vesting term and the contractual term of
 the option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Per ASC 718 &lt;i&gt;Share-Based Payments,&lt;/i&gt; market conditions must be
 considered in determining the estimated grant-date fair value of
 share-based payments and the market conditions must be considered
 in determining the requisite service period over which compensation
 cost is recognized. The Company estimates the fair value of the
 awards with market conditions using a Monte Carlo simulation, which
 utilizes several assumptions including the risk-free interest rate,
 the volatility of the Company&amp;#x2019;s stock and the exercise
 behavior of award recipients. The grant-date fair value of the
 awards is then recognized over the requisite service period, which
 represents the derived service period for the awards as determined
 by the Monte Carlo simulation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is required to include an estimate of the value of the
 awards that will be forfeited in calculating compensation costs,
 which the Company estimates based upon actual historical
 forfeitures. The forfeiture estimates are recognized over the
 requisite service period of the awards on a straight-line basis.
 Based upon these assumptions, the weighted-average grant date fair
 value of stock options granted to employees during the three months
 ended June&amp;#xA0;30, 2014 and 2013 was $0.77 and $1.76 per share,
 respectively. The weighted-average grant date fair value of stock
 options granted to employees during the six months ended
 June&amp;#xA0;30, 2014 and 2013 was $0.83 and $3.06 per share,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of June&amp;#xA0;30, 2014, there was $3.7 million of total
 unrecognized stock-based compensation expense related to stock
 options granted to employees under the Company&amp;#x2019;s 2002 Stock
 Incentive Plan and 2010 Stock Incentive Plan (collectively, the
 &amp;#x201C;Plans&amp;#x201D;). The expense is expected to be recognized over
 a weighted-average period of 2.2 years. No options were exercised
 during the three and six months ended June&amp;#xA0;30, 2014. The
 intrinsic value of options exercised was $0.2 million for the three
 months ended June&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The restricted stock activity for the six months ended
 June&amp;#xA0;30, 2014 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&amp;#xA0;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Fair-Value&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(133,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested/Released&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of June&amp;#xA0;30, 2014, there was $0.2 million of total
 unrecognized stock-based compensation expense related to restricted
 stock awards granted under the plans. The expense is expected to be
 recognized over a weighted-average period of 1.4 years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_884A2207-B421-4A8F-AC53-477042283A1B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For a discussion of recent accounting pronouncements adopted by the
 Company, please refer to Note 2, &amp;#x201C;Significant Accounting
 Policies,&amp;#x201D; included in the Company&amp;#x2019;s Annual Report on
 Form 10-K for the fiscal year ended December&amp;#xA0;31, 2013, filed
 with the SEC on March&amp;#xA0;13, 2014. The Company did not adopt any
 new accounting pronouncements during the three months ended
 June&amp;#xA0;30, 2014 that had a material effect on the
 Company&amp;#x2019;s condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB and the International Accounting Standards
 Board (IASB) (collectively, the &amp;#x201C;Boards&amp;#x201D;) jointly
 issued a comprehensive new revenue recognition standard that will
 supersede nearly all existing revenue recognition guidance under
 US&amp;#xA0;GAAP and IFRS. The standard is effective for public
 entities for annual and interim periods beginning after
 December&amp;#xA0;15, 2016. Early adoption is not permitted under US
 GAAP. The Company is currently evaluating what effect, if any, this
 standard will have on its revenue recognition policies and its
 financial statements, including how the standard will be
 adopted.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_F424621B-E286-4CEF-B920-CEB060676E1A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Available-for-sale securities at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,075&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,573&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Municipal bonds (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Asset-backed securities (Due within 1 year)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,007&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,682&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="Segment" decimals="INF" id="id_4941002_CBF4B7EC-BCAE-46D9-B4AA-9C8AF4E78265_2_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_EAEF5DF4-B3FF-4188-AE74-CA0BF2FB81F8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Under the Company&amp;#x2019;s stock-based compensation programs, the
 Company periodically grants stock options and restricted stock to
 employees, directors and nonemployee consultants. The Company also
 issues shares under an employee stock purchase plan. The fair value
 of all awards is recognized in the Company&amp;#x2019;s statements of
 operations over the requisite service period for each award. Awards
 that vest as the recipient provides service are expensed on a
 straight-line basis over the requisite service period. Other
 awards, such as performance-based awards that vest upon the
 achievement of specified goals, are expensed using the accelerated
 attribution method if achievement of the specified goals is
 considered probable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of equity-classified awards to employees and
 directors are measured at fair value on the date the awards are
 granted. Awards to nonemployee consultants are recorded at their
 fair values and are re-measured as of each balance sheet date until
 the recipient&amp;#x2019;s services are complete. During the three and
 six months ended June&amp;#xA0;30, 2014 and June&amp;#xA0;30, 2013, the
 Company recorded the following stock-based compensation
 expense:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;515&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(643&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;656&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense is allocated to research and
 development and general and administrative expense based upon the
 department of the employee to whom each award was granted. No
 related tax benefits of the stock-based compensation expense have
 been recognized.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_9F2E26E2-6726-4DE7-9DC2-105CE5F1BB7E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company records cash equivalents and marketable securities at
 fair value. The accounting standards for fair value measurements
 establish a hierarchy that distinguishes between fair value
 measurements based on market data (observable inputs) and those
 based on the Company&amp;#x2019;s own assumptions (unobservable inputs).
 The hierarchy consists of three levels:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Quoted market prices in
 active markets for identical assets or liabilities. Assets that are
 valued utilizing only Level 1 inputs include money market
 funds.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" align="left"&gt;Level 2&amp;#x2014;Inputs other than Level 1 inputs that are
 either directly or indirectly observable, such as quoted market
 prices, interest rates and yield curves. Assets that are valued
 utilizing Level 2 inputs include U.S. government agency securities,
 asset-backed securities, and corporate bonds, including commercial
 paper. These investments have been initially valued at the
 transaction price and are subsequently valued, at the end of each
 reporting period, utilizing third party pricing services or other
 observable market data. The pricing services utilize industry
 standard valuation models, including both income and market based
 approaches and observable market inputs to determine value. These
 observable market inputs include reportable trades, benchmark
 yields, credit spreads, broker/dealer quotes, bids, offers, current
 spot rates, and other industry and economic events. The Company
 validates the prices provided by third party pricing services by
 reviewing their pricing methods and matrices, obtaining market
 values from other pricing sources, analyzing pricing data in
 certain instances and confirming that the relevant markets are
 active. After completing its validation procedures, the Company did
 not adjust or override any fair value measurements provided by
 pricing services as of June&amp;#xA0;30, 2014 or December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Unobservable inputs
 developed using estimates and assumptions developed by the Company,
 which reflect those that a market participant would use. The
 Company made one nonrecurring fair value measurement associated
 with a lease exit liability. The Company currently has no assets or
 liabilities measured at fair value on a recurring basis that
 utilize Level 3 inputs.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following tables summarize the cash equivalents and marketable
 securities measured at fair value on a recurring basis in the
 accompanying consolidated balance sheets as of June&amp;#xA0;30, 2014
 and December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,767&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="Times:" nowrap="nowrap"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;of&amp;#xA0;Cash&amp;#xA0;Equivalents&amp;#xA0;and&lt;/b&gt;&lt;br /&gt;
 
 &lt;b&gt;Marketable Securities as of December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,503&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In 2014, the Company has recorded liabilities totaling $15.2
 million associated with the exit of portions of its leased
 facilities (refer to footnote 9). The Company measured the fair
 values of the liabilities based on the present value of the
 remaining lease payments less the amount of sublease income the
 Company estimates it could reasonably obtain. The Company estimated
 its future rental and operating expense payment obligations using
 the terms of its lease agreement and its historical share of the
 building&amp;#x2019;s expenses, adjusting for the effects of inflation.
 The estimated sublease income to be received is based upon market
 rates for comparable spaces in the Cambridge area. The net cash
 outflows over the remaining life of the lease were discounted using
 a credit-risk adjusted risk-free rate. The Company has classified
 these lease liabilities as Level 3 fair value measurements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the Company&amp;#x2019;s loans payable at
 June&amp;#xA0;30, 2014, computed pursuant to a discounted cash flow
 technique using the effective interest rate under the loan, is
 $14.1 million and is considered a Level 2 fair value measurement.
 The effective interest rate, which reflects the current market
 rate, considers the fair value of the warrant issued in connection
 with the loan, loan issuance costs and the deferred charge.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_22">11833000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_3_2">4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_29">6352000</us-gaap:RepaymentsOfDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_10">26000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_5">-18000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_23">38056000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_8">5000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestPaid contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_36">1040000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_10">251000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_0">17135000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_12">672000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_3_4">-24405000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_13">-192000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_7">-100000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_6">-23357000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnSaleOfSecuritiesNet contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_2_2">0</us-gaap:GainLossOnSaleOfSecuritiesNet>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_14">-46000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_463F0F04-9A6F-4710-A6E3-2F08988B84FE_1_1">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_11">-1052000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_12">-24409000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_8">-197000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_30">-6322000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_3">10400000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_6">1366000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_4">1690000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_31">-7464000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_19">-5563000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_25">34078000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:OperatingExpenses contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_5">40492000</us-gaap:OperatingExpenses>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_17">-17136000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_16">3763000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_9">1083000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_15">-738000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_18">7646000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_28">30000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_3">7600000</us-gaap:AssetImpairmentCharges>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_4">9025000</us-gaap:RestructuringCharges>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_24">83967000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_3_2">21067000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_463F0F04-9A6F-4710-A6E3-2F08988B84FE_1_0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_A847B5DC-8947-41A2-BAA3-D5131D41903B_2_0">7600000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <aveo:ReclassificationPolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_F91AF19D-561B-4013-B48D-9C39D161F0FF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has reclassified the tenant improvement allowance
 receivable from prepaid expenses and other current assets on the
 consolidated balance sheets at December&amp;#xA0;31, 2013 to a separate
 financial statement line to conform to the current period
 presentation.&lt;/p&gt;
 &lt;/div&gt;</aveo:ReclassificationPolicyPolicyTextBlock>
  <aveo:ScheduleOfLeaseTerminationCostTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_466D68B2-B1C1-433D-BEB8-563E8FFE21E9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of the
 Company&amp;#x2019;s lease exit activity recorded in current and
 long-term liabilities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Lease Exit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accretion&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amounts&lt;br /&gt;
 paid&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amounts&lt;br /&gt;
 accrued&amp;#xA0;at&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lease exit costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(797&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,632&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</aveo:ScheduleOfLeaseTerminationCostTableTextBlock>
  <aveo:CollaborativeAndLicenseArrangementDisclosureTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_626BB0F1-D9D7-4058-B732-104E09E71CE1_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;(4) Collaborations and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Biodesix&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In April 2014, the Company entered into a worldwide agreement with
 Biodesix to develop and commercialize its hepatocyte growth factor
 (&amp;#x201C;HGF&amp;#x201D;) inhibitory antibody ficlatuzumab, with
 Biodesix&amp;#x2019;s proprietary companion diagnostic test,
 VeriStrat&lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt;, a serum protein
 test that is commercially available to help physicians guide
 treatment decisions for patients with advanced non-small cell lung
 cancer (&amp;#x201C;NSCLC&amp;#x201D;).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the agreement, the Company granted Biodesix perpetual,
 non-exclusive rights to certain intellectual property, including
 all clinical and biomarker data related to ficlatuzumab, to develop
 and commercialize VeriStrat. Biodesix granted the Company
 perpetual, non-exclusive rights to certain intellectual property,
 including diagnostic data related to VeriStrat, with respect to the
 development and commercialization of ficlatuzumab; each license
 includes the right to sublicense, subject to certain exceptions.
 Pursuant to a joint development plan to be agreed upon by a joint
 steering committee, the Company retains primary responsibility for
 clinical development of ficlatuzumab in a proof of concept
 (&amp;#x201C;POC&amp;#x201D;) clinical study of ficlatuzumab for NSCLC, in
 which VeriStrat will be used to select clinical trial subjects,
 referred to as the NSCLC POC Trial. The NSCLC POC Trial will be
 fully funded by Biodesix up to a maximum of $15 million, referred
 to as the &amp;#x201C;Cap&amp;#x201D;. After the Cap is reached, the Company
 and Biodesix will share equally in the costs of the NSCLC trial,
 and the Company and Biodesix will each be responsible for 50% of
 development and regulatory costs associated with all future
 clinical trials agreed-upon by Biodesix and the Company, including
 all milestone payments and royalties payable to third parties, if
 any.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Pending marketing approval of ficlatuzumab and subject to a
 commercialization agreement to be entered into after receipt of
 results from the NSCLC POC Trial, each party would share equally in
 commercialization profits and losses, subject to the
 Company&amp;#x2019;s right to be the lead commercialization party.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Biodesix is solely responsible for the VeriStrat development costs,
 as well as VeriStrat sales and marketing costs. Subject to and
 following the approval of the VeriStrat test as a companion
 diagnostic for ficlatuzumab, Biodesix has agreed to make the
 VeriStrat test available and use commercially reasonable efforts to
 seek reimbursement in all geographies where ficlatuzumab is
 approved. The Company has agreed to reimburse Biodesix a
 pre-specified amount, under certain circumstances for VeriStrat
 tests performed.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Prior to the first commercial sale of ficlatuzumab and after the
 earlier of (i)&amp;#xA0;the Cap being reached or (ii)&amp;#xA0;the
 completion of the NSCLC POC Trial, each party has the right to
 elect to discontinue participating in further development or
 commercialization efforts with respect to ficlatuzumab, which is
 referred to as an &amp;#x201C;Opt-Out&amp;#x201D;. If either AVEO or Biodesix
 elects to Opt-Out, with such party referred to as the &amp;#x201C;Opting
 -Out Party&amp;#x201D;, then the Opting-Out Party shall not be
 responsible for any future costs associated with developing and
 commercializing ficlatuzumab other than any ongoing clinical
 trials. After election of an Opt-Out, the non-opting out party
 shall have sole decision-making authority with respect to further
 development and commercialization of ficlatuzumab. Additionally,
 the Opting-Out Party shall be entitled to receive, if ficlatuzumab
 is successfully developed and commercialized, a royalty equal to
 10% of net sales of ficlatuzumab throughout the world, if any,
 subject to offsets under certain circumstances.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 If Biodesix elects to Opt-Out, it will continue to be responsible
 for its development and commercialization obligations with respect
 to VeriStrat. If AVEO elects to Opt-Out, it will continue to make
 the existing supply of ficlatuzumab available to Biodesix for the
 purposes of enabling Biodesix to complete the development of
 ficlatuzumab, and Biodesix will have the right to commercialize
 ficlatuzumab.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Prior to any Opt-Out, the parties shall share equally in any
 payments received from a third party licensee; provided, however,
 after any Opt-Out, the Opting-Out Party shall be entitled to
 receive only a reduced portion of such third party payments. The
 agreement will remain in effect until the expiration of all payment
 obligations between the parties related to development and
 commercialization of ficlatuzumab, unless earlier terminated.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Activities under the agreement with Biodesix were evaluated under
 ASC 605-25 &lt;i&gt;Revenue Recognition&amp;#x2014;Multiple Element
 Arrangements&lt;/i&gt;, or ASC 605-25, to determine whether such
 activities represented a multiple element revenue arrangement. The
 agreement with Biodesix includes the following non-contingent
 deliverables: perpetual, non-exclusive rights to certain
 intellectual property including clinical and biomarker data related
 to ficlatuzumab for use in developing and commercializing
 VeriStrat; the Company&amp;#x2019;s obligation to deliver technology
 improvements and data developed during the NSCLC POC Trial to
 Biodesix; the Company&amp;#x2019;s obligation to participate in the
 joint steering committee during the NSCLC POC Trial; the
 Company&amp;#x2019;s obligation to perform certain development
 activities associated with the NSCLC POC Trial; and the
 Company&amp;#x2019;s obligation to supply clinical material for use in
 conducting the NSCLC POC Trial; and the Company&amp;#x2019;s obligation
 to deliver clinical specimens and data during the NSCLC POC Trial.
 The Company concluded that any deliverables that would be delivered
 after the NSCLC POC Trial is complete are contingent deliverables
 because these services are contingent upon the results of the NSCLC
 POC Trial. As these deliverables are contingent, and are not at an
 incremental discount, they are not evaluated as deliverables at the
 inception of the arrangement. These contingent deliverables will be
 evaluated and accounted for separately as each related contingency
 is resolved. As of June&amp;#xA0;30, 2014, no contingent deliverables
 had been provided by the Company.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company determined that the delivered item, or the perpetual,
 non-exclusive rights to certain intellectual property for use in
 developing and commercializing VeriStrat did not have standalone
 value from the remaining deliverables since the customer could not
 obtain the intended benefit of the license without the remaining
 deliverables. Since the remaining deliverables will be performed
 over the same period of performance there is no difference in
 accounting for the deliverables as one unit or multiple units of
 accounting, and therefore, the Company is accounting for the
 deliverables as one unit of accounting.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company records the consideration earned while conducting the
 NSCLC POC Trial, which consists of reimbursements of Biodesix for
 expenses related to the trial under the Cap, as a reduction to
 research and development expense using the proportional performance
 method over the respective period of performance. As a result of
 the cost sharing provisions in the agreement, the Company reduced
 research and development expenses by approximately $0.2 million
 during the three and six months ended June&amp;#xA0;30, 2014. The
 amount due to the Company from Biodesix pursuant to the
 cost-sharing provision was $0.2 million at June&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Astellas Pharma&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In February 2011, the Company, together with its wholly-owned
 subsidiary AVEO Pharma Limited, entered into a Collaboration and
 License Agreement with Astellas (the &amp;#x201C;Astellas
 Agreement&amp;#x201D;), pursuant to which the Company and Astellas
 intended to develop and commercialize tivozanib for the treatment
 of a broad range of cancers. Under the terms of the Astellas
 Agreement, the Company and Astellas shared responsibility for
 continued development and commercialization of tivozanib in North
 America and in Europe under a joint development plan and a joint
 commercialization plan, respectively. Throughout the rest of the
 world (the &amp;#x201C;Royalty Territory&amp;#x201D;), excluding Asia, where
 Kyowa Hakko Kirin (&amp;#x201C;KHK&amp;#x201D;) has retained all development
 and commercialization rights, Astellas has an exclusive,
 royalty-bearing license to develop and commercialize tivozanib. The
 terms of the Astellas Agreement are subject to the Company&amp;#x2019;s
 obligations to KHK under a license agreement entered into with KHK
 in 2006 pursuant to which the Company acquired exclusive rights to
 develop and commercialize tivozanib worldwide outside of Asia.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2013, the Company received a complete response letter from
 the FDA informing the Company that the FDA will not approve in its
 present form the Company&amp;#x2019;s NDA for tivozanib for the
 treatment of patients with advanced renal cell carcinoma, or RCC.
 In January 2014, AVEO and Astellas jointly decided to discontinue a
 Phase 2 breast cancer clinical trial due to insufficient
 enrollment. Further, Astellas elected in February 2014 to terminate
 the Astellas Agreement as a result of the limited scope of
 development for tivozanib moving forward. This termination will be
 effective on August&amp;#xA0;11, 2014, at which time the tivozanib
 rights will be returned to the Company. In accordance with the
 Astellas Agreement, committed development costs, including the
 costs of winding down discontinued tivozanib clinical development
 programs, will be shared equally. There are no refund provisions in
 the Astellas Agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the Astellas Agreement, the Company received an initial cash
 payment of $125.0 million, comprised of a $75.0 million license fee
 and $50.0 million in research and development funding. The Company
 retained net proceeds of approximately $97.6 million of the initial
 cash payment from Astellas, after payments to KHK and strategic,
 legal and financial advisors. In December 2012, the Company
 received a $15.0 million milestone payment from Astellas in
 connection with the acceptance by the FDA of the NDA filing for
 tivozanib. The milestone was considered substantive and revenue was
 recognized upon achievement of the milestone.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is accounting for the joint development and
 commercialization activities in North America and Europe as a joint
 risk-sharing collaboration in accordance with ASC 808,
 &lt;i&gt;Collaborative Arrangements&lt;/i&gt;. In addition, these activities
 were not deemed to be separate deliverables under the Astellas
 Agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Payments from Astellas with respect to Astellas&amp;#x2019; share of
 tivozanib development and commercialization costs incurred by the
 Company pursuant to the joint development plan are recorded as a
 reduction to research and development expense and general and
 administrative expense in the accompanying consolidated financial
 statements due to the joint risk-sharing nature of the activities
 in North America and Europe. As a result of the cost-sharing
 provisions in the Astellas Agreement, the Company reduced research
 and development expense by $1.1 million and $6.4 million during the
 three months ended June&amp;#xA0;30, 2014 and 2013, respectively, and
 by $2.3 million and $12.7 million during the six months ended
 June&amp;#xA0;30, 2014 and 2013, respectively. The Company also reduced
 general and administrative expense by $8,000 and $1.0 million
 during the three months ended June&amp;#xA0;30, 2014 and 2013,
 respectively, and by $0.1 million and $2.3 million during the six
 months ended June&amp;#xA0;30, 2014 and 2013, respectively, as a result
 of the cost-sharing provisions in the Astellas Agreement. The net
 amount due to the Company from Astellas pursuant to the
 cost-sharing provisions was $1.0&amp;#xA0;million at June&amp;#xA0;30,
 2014.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Activities under the Astellas Agreement outside of the joint
 development and commercialization activities in North America and
 Europe, including the co-exclusive license to develop and
 commercialize tivozanib in North America and Europe that was
 delivered prior to the initiation of the collaborative activities
 in North America and Europe, were evaluated under ASC 605-25 to
 determine if they represented a multiple element revenue
 arrangement. The Astellas Agreement includes the following
 deliverables: (1)&amp;#xA0;a co-exclusive license to develop and
 commercialize tivozanib in North America and Europe (the
 &amp;#x201C;License Deliverable&amp;#x201D;); (2)&amp;#xA0;a combined deliverable
 comprised of an exclusive royalty-bearing license to develop and
 commercialize tivozanib in the Royalty Territory and the
 Company&amp;#x2019;s obligation to provide access to clinical and
 regulatory information resulting from the activities in North
 America and Europe to Astellas for its development and
 commercialization of tivozanib in the Royalty Territory (the
 &amp;#x201C;Royalty Territory Deliverable&amp;#x201D;); and (3)&amp;#xA0;the
 Company&amp;#x2019;s obligation to supply clinical material to Astellas
 for development of tivozanib in the Royalty Territory (the
 &amp;#x201C;Clinical Material Deliverable&amp;#x201D;). All of these
 deliverables were deemed to have stand-alone value and to meet the
 criteria to be accounted for as separate units of accounting under
 ASC 605-25. Factors considered in this determination included,
 among other things, the subject of the licenses and the research
 and development and commercial capabilities of Astellas.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company allocated the up-front consideration of $125.0 million
 to the deliverables based on management&amp;#x2019;s best estimate of
 selling price of each deliverable using the relative selling price
 method as the Company did not have VSOE or TPE of selling price for
 such deliverables. The Company&amp;#x2019;s best estimate of selling
 price considered discounted cash flow models, the key assumptions
 of which included the market opportunity for commercialization of
 tivozanib in North America and Europe and the Royalty Territory,
 the probability of successfully developing and commercializing
 tivozanib, the remaining development costs for tivozanib, and the
 estimated time to commercialization of tivozanib. The Company
 allocated up-front consideration of $120.2 million to the License
 Deliverable and up-front consideration of $4.8 million to the
 Royalty Territory Deliverable. The relative selling price of the
 Company&amp;#x2019;s obligation under the Clinical Material Deliverable
 had &lt;i&gt;de minimis&lt;/i&gt; value.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recorded the $120.2 million relative selling price of
 the License Deliverable as collaboration revenue during the three
 months ended March&amp;#xA0;31, 2011 upon delivery of the license, and
 deferred approximately $4.8 million of revenue representing the
 relative selling price of the Royalty Territory Deliverable. The
 Company was recording the $4.8 million of revenue attributed to the
 Royalty Territory Deliverable ratably over the Company&amp;#x2019;s
 period of performance through April 2022, the remaining patent life
 of tivozanib. Upon being notified that the collaboration would be
 terminated effective August 2014, the Company reassessed the period
 of performance associated with the Royalty Territory Deliverable
 and accelerated the recognition of the remaining deferred revenue
 such that the balance would be recognized through August 2014. This
 change in estimate resulted in the recognition of an additional
 $1.7 million during the three months ended June&amp;#xA0;30, 2014, and
 an additional $2.6 million during the six months ended
 June&amp;#xA0;30, 2014. The Company recorded approximately $1.8 million
 and $0.1 million of revenue associated with the Royalty Territory
 Deliverable during the three month periods ended June&amp;#xA0;30, 2014
 and 2013, respectively, and approximately $2.8 million and $0.2
 million of revenue associated with the Royalty Territory
 Deliverable during each of the six month periods ended
 June&amp;#xA0;30, 2014 and 2013, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the agreement, the Company received cash payments related to
 up-front license fees, reimbursable payments and milestone payments
 of $1.2 million and $7.8 million during the three months ended
 June&amp;#xA0;30, 2014 and 2013, respectively, and received payments of
 $2.2 million and $26.5 million during the six months ended
 June&amp;#xA0;30, 2014 and 2013, respectively.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Biogen Idec International GmbH&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In March 2009, the Company entered into an exclusive option and
 license agreement with Biogen Idec International GmbH, a subsidiary
 of Biogen Idec Inc., (collectively &amp;#x201C;Biogen Idec&amp;#x201D;)
 regarding the development and commercialization of the
 Company&amp;#x2019;s discovery-stage ErbB3-targeted antibodies for the
 potential treatment and diagnosis of cancer and other diseases
 outside of North America. Under the agreement, the Company is
 responsible for developing ErbB3 antibodies through completion of
 the first phase 2 clinical trial designed in a manner that, if
 successful, will generate data sufficient to support advancement to
 a phase 3 clinical trial.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In March 2014, the Company and Biogen Idec amended the exclusive
 option and license agreement (the &amp;#x201C;Amendment&amp;#x201D;).
 Pursuant to the Amendment, Biogen agreed to the termination of its
 rights and obligations under the agreement, including
 Biogen&amp;#x2019;s option to (i)&amp;#xA0;obtain a co-exclusive (with AVEO)
 worldwide license to develop and manufacture ErbB3 targeted
 antibodies and (ii)&amp;#xA0;obtain exclusive commercialization rights
 to ErbB3 products in countries in the world other than North
 America. As a result, AVEO has worldwide rights to AV-203. Pursuant
 to the Amendment, AVEO is obligated to use reasonable efforts to
 seek a collaboration partner for the purpose of funding further
 development and commercialization of ErbB3 targeted antibodies.
 AVEO is also obligated to pay Biogen a percentage of milestone
 payments received by AVEO from future partnerships after
 March&amp;#xA0;28, 2016 and single digit royalty payments on net sales
 related to the sale of ErbB3 products, if any, up to cumulative
 maximum amount of $50 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The deliverables under the original arrangement included an option
 for a co-exclusive, worldwide license to develop and manufacture
 ErbB3 antibody products and an option for an exclusive license to
 commercialize ErbB3 antibody products in all countries in the world
 other than North America. The Company determined that these
 deliverables did not have standalone value due to the fact that the
 program was still in preclinical development and required the
 Company&amp;#x2019;s experience to advance development of the product
 candidates. As such, the Company determined that the original
 agreement should be accounted for as one unit of accounting.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the terms of the original agreement, Biogen Idec made
 up-front and milestone-based cash payments totaling $20.0 million.
 Of the $20.0 million received, $10.0 million was associated with
 milestones that were considered substantive and these amounts were
 included in revenue for the quarters ended March&amp;#xA0;31, 2010 and
 June&amp;#xA0;30, 2011, respectively. The remaining $10.0 million was
 amortized as additional license revenue over our period of
 substantial involvement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company concluded that the Amendment materially modified the
 terms of the agreement and, as a result, required application of
 ASC 605-25. Based upon the terms of the Amendment, the remaining
 deliverables included the Company&amp;#x2019;s obligation to seek a
 collaboration partner to fund further development of the program
 and the Company&amp;#x2019;s obligation to continue development and
 commercialization of the licensed products if a collaboration
 partner is secured (&amp;#x201C;Development Deliverable&amp;#x201D;). The
 Company concluded that its obligation to use best efforts to seek a
 collaboration partner does not have standalone value from the
 Development Deliverable upon delivery and thus the deliverables
 should be treated as a single unit of accounting.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon modifying the arrangement, the Company had $14.7 million of
 deferred revenue remaining to be amortized. The Company is not
 entitled to receive any further consideration from Biogen Idec
 under the amended arrangement. The Company allocated a portion of
 the remaining deferred revenue to the undelivered unit of
 accounting based upon the Company&amp;#x2019;s best estimate of the
 selling price, as the Company determined that neither VSOE or TPE
 were available. The Company determined the best estimate of selling
 price to be approximately $0.6 million and recognized the remaining
 $14.3 million as collaboration revenue in the six months ended
 June&amp;#xA0;30, 2014. The deferred revenue associated with the
 undelivered unit of accounting is being recognized on a
 straight-line basis over the expected period of performance, or
 through December 2015 based upon the Company&amp;#x2019;s historical
 experience with marketing its product candidates to potential
 partners.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The best estimate of selling price was based upon a cost approach
 pursuant to which the Company estimated the costs expected to be
 incurred in executing a partnership agreement and then applied a
 reasonable markup. The Company estimated future cash outflows for
 several possible outcomes, including the execution of a partnership
 at different times within a reasonable range and partnerships of
 differing complexity. The Company estimated its cash outflows for
 each scenario based upon the expected costs associated with the
 relevant employees and the expected level of effort to be expended
 to seek and execute a partnership. The Company&amp;#x2019;s analysis
 also considered the legal charges that it anticipates it will
 incur. Changes to the Company&amp;#x2019;s assumptions within the
 reasonable range of possible values would not have a material
 impact on the amounts recorded in current or future periods.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the agreement, the Company recorded revenue of $0.1 million
 and $14.4 million during the three and six month periods ended
 June&amp;#xA0;30, 2014, respectively, and $0.2 million and $0.4 million
 during the three and six month periods ended June&amp;#xA0;30, 2013,
 respectively.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Kirin Brewery&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In December 2006, the Company entered into an exclusive license
 agreement, with the right to grant sublicenses, subject to certain
 restrictions, with Kirin Brewery Co. Ltd. (now Kyowa Hakko Kirin)
 (&amp;#x201C;KHK&amp;#x201D;) to research, develop, manufacture and
 commercialize tivozanib, pharmaceutical compositions thereof and
 associated biomarkers in all territories in the world except for
 Asia (the &amp;#x201C;KHK Agreement&amp;#x201D;). Upon entering into the KHK
 Agreement, the Company made a cash payment in the amount of $5.0
 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In March 2010, the Company made a $10.0 million milestone payment
 to KHK in connection with the dosing of the first patient in the
 Company&amp;#x2019;s phase 3 clinical trial of tivozanib. The Company
 recorded $22.5&amp;#xA0;million of research and development expense
 during the year ended December&amp;#xA0;31, 2011 associated with a
 payment made to KHK related to the up-front license payment
 received under the Astellas Agreement. In December 2012, the
 Company made a $12.0 million milestone payment to KHK in connection
 with the acceptance by the FDA of the Company&amp;#x2019;s NDA filing
 for tivozanib, all of which was expensed as research and
 development expense during the year ended December&amp;#xA0;31, 2012.
 In connection with this payment, $6.0 million was reimbursed from
 Astellas and recorded as a reduction of research and development
 expense.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the KHK Agreement, the Company may be required to
 (i)&amp;#xA0;make future milestone payments upon the achievement of
 specified regulatory milestones and (ii)&amp;#xA0;pay tiered royalty
 payments on net sales it makes of tivozanib in its territory
 ranging from the low to mid-teens as a percentage of the
 Company&amp;#x2019;s net sales of tivozanib. In the event the Company
 sublicenses the rights licensed to the Company under the KHK
 Agreement (after the termination of the agreement with Astellas in
 August 2014), the Company is required to pay KHK a specified
 percentage of any amounts the Company receives from any third party
 sublicensees, other than amounts the Company receives in respect of
 research and development funding or equity investments, subject to
 certain limitations.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;St. Vincent&amp;#x2019;s Hospital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, the Company entered into a license agreement with St.
 Vincent&amp;#x2019;s Hospital Sydney Limited (&amp;#x201C;St.
 Vincent&amp;#x2019;s&amp;#x201D;), under which the Company obtained an
 exclusive, worldwide license to research, develop, manufacture and
 commercialize products for human therapeutic, preventative and
 palliative applications that benefit from inhibition or decreased
 expression or activity of MIC-1, which is also referred to as
 GDF15. The Company believes GDF15 is a novel target for cachexia
 and the Company is exploiting this license in its AV-380 program
 for cachexia. Under the agreement, the Company has the right to
 grant sublicenses subject to certain restrictions. The Company has
 a right of first negotiation to obtain an exclusive license to
 certain improvements that St. Vincent&amp;#x2019;s or third parties may
 make to licensed therapeutic products. Under the license agreement,
 St. Vincent&amp;#x2019;s also granted the Company non-exclusive rights
 for certain related diagnostic products and research tools.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the license agreement, the Company is obligated to use
 diligent efforts to conduct research and clinical development and
 commercially launch at least one licensed therapeutic product, and
 to maximize profits from licensed therapeutic products for the
 benefit of the Company and St. Vincent&amp;#x2019;s. Subject to certain
 conditions, the Company has also agreed to achieve specified
 research, development and regulatory milestones by specified dates.
 If the Company does not achieve a given milestone by the agreed
 date, the Company has the option of paying the amount the Company
 would have been obligated to pay had the Company timely achieved
 the milestone, and, if the Company does so, St. Vincent&amp;#x2019;s
 will not have the right to terminate the license agreement based on
 its failure to timely achieve such milestone.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has also agreed that, for as long as there is a valid
 claim in the licensed patents, the Company will not, and the
 Company will ensure that its affiliates and its sublicensees do
 not, develop or commercialize any product, other than a licensed
 therapeutic product, for the treatment, prevention or prophylaxis
 of cachexia, decreased appetite or body weight, that binds to GDF15
 or the GDF15 receptor and that is a GDF15 antagonist, and will not
 license or induce any other person to do the same.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with entering into the license agreement with St.
 Vincent&amp;#x2019;s, the Company paid St. Vincent&amp;#x2019;s an upfront
 license fee of $0.7 million and a low five-figure amount to
 reimburse St. Vincent&amp;#x2019;s for patent-related expenses it
 incurred with respect to a specified licensed patent.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the Company&amp;#x2019;s license agreement with St.
 Vincent&amp;#x2019;s, the Company may be required to:&lt;/p&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;make milestone payments, up to an
 aggregate total of $9.2 million, upon achievement of specified
 research, development and regulatory milestones for the first three
 indications for licensed therapeutic products, some of which
 payments may be increased by a mid to high double-digit percentage
 rate for milestones payments made after the Company grants any
 sublicense under the license agreement, depending on the
 sublicensed territory or territories;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left" style="font-family:Times New Roman; font-size:10pt"&gt;pay tiered royalty
 payments equal to a low-single-digit percentage of any net sales
 the Company or its sublicensees make of licensed therapeutic
 products. The royalty rate escalates within the low-single-digit
 range during each calendar year based on increasing licensed
 therapeutic product sales during such calendar year. The
 Company&amp;#x2019;s royalty payment obligations for a licensed
 therapeutic product in a particular country end on the later of 10
 years after the date of first commercial sale of such licensed
 therapeutic product in such country or expiration of the
 last-to-expire valid claim of the licensed patents covering such
 licensed therapeutic product in such country, and are subject to
 offsets under certain circumstances;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;pay St. Vincent&amp;#x2019;s sublicensing
 fees of up to an aggregate amount in the low-to-mid six-digits,
 depending on the sublicensed territory or territories, at the time
 the Company grants any sublicense; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;reimburse St. Vincent&amp;#x2019;s for
 some or all of the reasonable costs and expenses it incurs in
 patent management, filing, prosecuting and maintaining the licensed
 patents.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The license agreement will remain in effect until the later of 10
 years after the date of first commercial sale of licensed
 therapeutic products in the last country in which a commercial sale
 is made, or expiration of the last-to-expire valid claim of the
 licensed patents, unless the Company elects, or St. Vincent&amp;#x2019;s
 elects, to terminate the license agreement earlier.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Either party has the right to terminate the agreement in connection
 with a material breach of the agreement by the other party that
 remains uncured for a specified cure period, or in connection with
 events relating to the other party&amp;#x2019;s insolvency or
 bankruptcy, or if a force majeure event continues for more than
 four months.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 St. Vincent&amp;#x2019;s has the right to terminate the agreement due to
 any patent-related challenge by the Company, its affiliates or any
 sublicensee, or if the Company or its affiliates or any sublicensee
 cause or induce any other person to make a patent-related
 challenge, and such challenge continues after a specified cure
 period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has the right to terminate the agreement on six
 months&amp;#x2019; notice if the Company terminates its GDF15 research
 and development programs as a result of the failure of a licensed
 therapeutic product in pre-clinical or clinical development, or if
 the Company forms the reasonable view that further GDF15 research
 and development is not commercially viable, and the Company is not
 then in breach of any of its obligations under the agreement. If
 the Company forms the reasonable view that further GDF15 research
 and development is not commercially viable and terminate the
 agreement before the Company starts a phase 1 clinical trial on a
 licensed therapeutic product, the Company will be required to pay
 St. Vincent&amp;#x2019;s a low-to-mid six-figure termination
 payment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Any termination of the agreement, in whole or in part, will result
 in a loss of the Company&amp;#x2019;s rights to the relevant licensed
 patents and know-how. If St. Vincent&amp;#x2019;s terminates the
 agreement in its entirety due to the Company&amp;#x2019;s breach,
 insolvency or a patent-related challenge, or the Company terminates
 the agreement due to a development failure or lack of commercial
 viability, as described above, St. Vincent&amp;#x2019;s will have a
 non-exclusive license from the Company to certain intellectual
 property rights and know-how relating to the licensed therapeutic
 products, and the Company must transfer to St. Vincent&amp;#x2019;s
 certain then-existing regulatory approvals and related documents
 for the licensed therapeutic products.&lt;/p&gt;
 &lt;/div&gt;</aveo:CollaborativeAndLicenseArrangementDisclosureTextBlock>
  <aveo:DistributionOfEquityInterests contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_9E27D0DB-DF2D-4F10-9F76-860640E633C8_2_1">2000000</aveo:DistributionOfEquityInterests>
  <aveo:IncreaseDecreaseInTenantImprovementAllowanceReceivableCurrent contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_591851F2-A8B0-4232-ACD6-3F4AFF23A42E_1_11">9069000</aveo:IncreaseDecreaseInTenantImprovementAllowanceReceivableCurrent>
  <aveo:FacilityLeaseExitObligationDisclosureTextBlockTableTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_B9B31D36-A44E-41A7-B135-2D2F12B41BCA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(9) Facility Lease Exit&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 During the six months ending June&amp;#xA0;30, 2014, the Company
 completed the planned build-out of portions of the office space it
 currently leases at its 650 E. Kendall Street facility. Upon
 completion of these build-outs, the Company ceased use of these
 spaces and recorded liabilities totaling $15.2 million. The fair
 value of these liabilities was determined using the credit-adjusted
 risk-free rate to discount the estimated future net cash outflows
 associated with the space that met the cease use criteria. The
 estimate of future net cash outflows included the Company&amp;#x2019;s
 expected minimum rental payments and incremental operating, utility
 and tax payments to the landlord less the amount of sublease income
 that the Company estimates it could reasonably expect to obtain
 during the remainder of the lease period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of the
 Company&amp;#x2019;s lease exit activity recorded in current and
 long-term liabilities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Lease Exit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accretion&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Expense&lt;br /&gt;
 incurred&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amounts&lt;br /&gt;
 paid&lt;br /&gt;
 during&amp;#xA0;the&amp;#xA0;six&lt;br /&gt;
 months&amp;#xA0;ended&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amounts&lt;br /&gt;
 accrued&amp;#xA0;at&lt;br /&gt;
 June 30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lease exit costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(797&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,632&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The total expense associated with recording the fair value of lease
 exit liabilities of $9.2 million and $15.2 million for the three
 and six months ending June&amp;#xA0;30, 2014, respectively, has been
 recorded within Restructuring and Lease Exit expense on the
 Condensed Consolidated Statements of Operations. The Company
 wrote-off $9.3 million and $14.0 million of deferred rent
 associated with the portions of the facility that met the cease use
 criteria under ASC 420-10 during the three and six months ending
 June&amp;#xA0;30, 2014, respectively. Further, the Company wrote-off
 leasehold improvements totaling $5.1 million and $7.6 million
 during the three and six months ending June&amp;#xA0;30, 2014,
 respectively. These transactions resulted in net charges of $5.0
 million and $8.8 million being recorded during the three and six
 months ended June&amp;#xA0;30, 2014, respectively. The Company also
 recorded $0.3 million of accretion expense during the three and six
 months ended June&amp;#xA0;30, 2014. Approximately $7.0 million of the
 amounts are reflected within accrued expenses on the consolidated
 balance sheet and the remaining $7.6 million has been recorded
 within other noncurrent liabilities on the consolidated balance
 sheet.&lt;/p&gt;
 &lt;/div&gt;</aveo:FacilityLeaseExitObligationDisclosureTextBlockTableTextBlock>
  <aveo:TenantImprovementAllowanceReceivablePolicyPolicyTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0" id="id_4941002_CE4CC73B-968F-4C70-85A9-2DE299523D93_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Tenant Improvement Allowance Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is entitled to be reimbursed by the Company&amp;#x2019;s
 landlord for certain expenditures associated with improvements made
 to its leased facility at 650 E. Kendall Street in Cambridge,
 Massachusetts. These receivables are recorded in the period that
 the improvements are made and the reimbursement is earned.&lt;/p&gt;
 &lt;/div&gt;</aveo:TenantImprovementAllowanceReceivablePolicyPolicyTextBlock>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712080x707836_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_1003_1">100000</aveo:DecreaseInExpenseDuringThePeriod>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712080x713040_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_2003_0">2300000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x770429_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_069416A2-B741-424A-A20D-B102780271D9_1001_0">120200000</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
  <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_069416A2-B741-424A-A20D-B102780271D9_2001_1">4800000</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2003_4">2800000</us-gaap:DeferredRevenueRevenueRecognized>
  <aveo:DeferredRevenuePeriodOfRecognition contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x828573_712375x1077987" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2003_2">Through April 2022</aveo:DeferredRevenuePeriodOfRecognition>
  <aveo:AdditionalDeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2003_3">2600000</aveo:AdditionalDeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_53C780B7-7A9E-4AB2-9706-AF3AF4EC597C_1003_0">2200000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:CostOfReimbursableExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x812407_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_38D211AC-7315-43E5-ACF5-C381FEEE56F2_2004_3">6000000</us-gaap:CostOfReimbursableExpense>
  <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281" unitRef="iso4217_USD" decimals="-5" id="id_4941002_D10625BA-292D-4806-B27F-F3E25C3FD2A0_1001_1">600000</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281" unitRef="iso4217_USD" decimals="-5" id="id_4941002_D10625BA-292D-4806-B27F-F3E25C3FD2A0_1001_2">14300000</us-gaap:DeferredRevenueRevenueRecognized>
  <aveo:DeferredRevenueAmortization contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281" unitRef="iso4217_USD" decimals="-5" id="id_4941002_D10625BA-292D-4806-B27F-F3E25C3FD2A0_1001_0">14700000</aveo:DeferredRevenueAmortization>
  <us-gaap:RoyaltyExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281_711502x716112" unitRef="iso4217_USD" decimals="-6" id="id_4941002_70B1FDBC-CD8C-47FE-92D8-163031634A8A_1001_0">50000000</us-gaap:RoyaltyExpense>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_E9447C42-D6AF-4909-BFD0-FE0411782CD7_1002_0">14400000</us-gaap:DeferredRevenueRevenueRecognized>
  <aveo:DeferredRevenueAmortization contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_0E762A67-33DE-4E9A-8867-A068B34DE4BF_2004_1">10000000</aveo:DeferredRevenueAmortization>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x891464_712080x713040_712375x891398" unitRef="iso4217_USD" decimals="-5" id="id_4941002_F9057CF0-AA7F-4E3D-9B1D-06A7F53C3C91_1002_0">200000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1001_4">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1001_0">0.7206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x711169" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_1001_2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <aveo:MarketableSecuritiesMaturityTerm contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x711169" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_1002_0">P3M</aveo:MarketableSecuritiesMaturityTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2001_5">0.0202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2001_1">0.7398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x716112" id="id_4941002_A187C5BB-5CD7-4C01-B358-B700E8B5636E_2001_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <aveo:MarketableSecuritiesMaturityTerm contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x716112" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_2002_1">P24M</aveo:MarketableSecuritiesMaturityTerm>
  <us-gaap:BusinessExitCosts1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7F7D1A31-2BCA-4061-AD7E-62F4D5EC8151_1001_0">15154000</us-gaap:BusinessExitCosts1>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_1002_3">8800000</us-gaap:RestructuringCharges>
  <us-gaap:AccretionExpense contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-3" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_1002_5">275000</us-gaap:AccretionExpense>
  <aveo:CashPaid contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-3" id="id_4941002_3427E53E-C979-4A79-BD09-334D254A8F57_2001_3">797000</aveo:CashPaid>
  <us-gaap:GainLossOnContractTermination contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923_715990x770350" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_2002_2">7600000</us-gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923_715990x799157" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_3002_1">14000000</us-gaap:GainLossOnContractTermination>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x717013" unitRef="iso4217_USD" decimals="-3" id="id_4941002_8C981AF1-CD76-45C3-A6C5-2A7395CB949A_4001_3">553000</us-gaap:PaymentsForRestructuring>
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x717013" unitRef="iso4217_USD" xsi:nil="true" id="id_4941002_8C981AF1-CD76-45C3-A6C5-2A7395CB949A_4001_2" />
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_712080x707836_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_1003_1">851000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_712080x713040_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_2003_0">515000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x708980" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_E9FB46F7-9DF0-4A76-B974-C0B591DFF7B4_1003_0">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x708980" id="id_4941002_BFA44916-6342-4664-8B04-FB622A6107BE_1001_1">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x708980" unitRef="iso4217_USD" decimals="-5" id="id_4941002_BFA44916-6342-4664-8B04-FB622A6107BE_1001_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_5001_4">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="shares" decimals="INF" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_5001_400006">73280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_5001_6">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_5001_3">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" id="id_4941002_112F8990-910F-4750-ADAB-24DB82965206_1001_1">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="shares" decimals="INF" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_5001_400004">133420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="shares" decimals="INF" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_5001_400003">501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <aveo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="shares" xsi:nil="true" id="id_4941002_B918275D-8960-423E-B85B-6505FA07EB9F_5001_5" />
  <aveo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_4941002_EF1CCE0C-FE71-40E1-B762-5D6E1FE2FE94_5001_5" />
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x863784" id="id_4941002_57A37E18-3834-45CA-B9FF-B1DD7361450A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the three and six months ended June&amp;#xA0;30, 2014 and
 June&amp;#xA0;30, 2013, the Company recorded the following stock-based
 compensation expense:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;515&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(643&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;656&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_3_2">1366000</us-gaap:ShareBasedCompensation>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712124x714298_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_722D2604-ED59-40E6-A81F-05E1955AE2E2_1001_1">75000000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712124x791210_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_722D2604-ED59-40E6-A81F-05E1955AE2E2_3001_2">50000000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_722D2604-ED59-40E6-A81F-05E1955AE2E2_4001_0">125000000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_722D2604-ED59-40E6-A81F-05E1955AE2E2_4001_3">97600000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE672770--1410-Q0005_STD_28_20100630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_4_5">800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE672770--1410-Q0005_STD_30_20140630_0" unitRef="shares" decimals="INF" id="id_4941002_BAB0D972-1665-4F85-BB24-8AD9FCF1528F_1_0">2250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_30_20140630_0_712080x1077456" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_1005_0">1200000</us-gaap:InterestExpense>
  <aveo:TerminationNoticePeriod contextRef="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712124x714218_712375x707810" id="id_4941002_036032BE-5C2C-43A3-907E-C4DD4189D0C3_1001_0">P6M</aveo:TerminationNoticePeriod>
  <aveo:InitialLicenseAgreementAndMilestonePayment contextRef="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712124x714298_712375x707810" unitRef="iso4217_USD" decimals="-5" id="id_4941002_E96C20DC-B3B3-4F4F-AA1B-8A9BD60419D3_1001_0">700000</aveo:InitialLicenseAgreementAndMilestonePayment>
  <aveo:ContractExpirationTermFromFirstCommercialSaleOfCertainProduct contextRef="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712375x707810" id="id_4941002_AB07428E-2E72-4113-BAE6-0CC0609308A7_1001_0">P10Y</aveo:ContractExpirationTermFromFirstCommercialSaleOfCertainProduct>
  <aveo:TerminationPeriodInCaseOfBreachOfContract contextRef="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712375x707810" id="id_4941002_5201FAC6-B5D3-421B-AB0C-F570AABF69EF_1001_0">P4M</aveo:TerminationPeriodInCaseOfBreachOfContract>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_31_20090331_0_705999x840210_712124x714298_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_0E762A67-33DE-4E9A-8867-A068B34DE4BF_1001_0">20000000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_31_20120331_0_712080x1077456" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CF59B854-4FB7-4DEC-9A1D-947F678B5045_1006_0">1300000</us-gaap:InterestExpense>
  <aveo:MilestonePayment contextRef="eol_PE672770--1410-Q0005_STD_31_20100331_0_705999x812407_712375x707810" unitRef="iso4217_USD" decimals="-5" id="id_4941002_38D211AC-7315-43E5-ACF5-C381FEEE56F2_1002_0">10000000</aveo:MilestonePayment>
  <aveo:InitialLicenseAgreementAndMilestonePayment contextRef="eol_PE672770--1410-Q0005_STD_31_20061231_0_705999x812407_712375x707810" unitRef="iso4217_USD" decimals="-5" id="id_4941002_81D690F4-2BEE-49C0-9AFC-1AE04616A8B8_1001_0">5000000</aveo:InitialLicenseAgreementAndMilestonePayment>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_31_20121231_0_705999x740949_712124x756018_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_722D2604-ED59-40E6-A81F-05E1955AE2E2_2002_4">15000000</us-gaap:DeferredRevenueAdditions>
  <aveo:MilestonePayment contextRef="eol_PE672770--1410-Q0005_STD_31_20121231_0_705999x812407_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_38D211AC-7315-43E5-ACF5-C381FEEE56F2_2003_2">12000000</aveo:MilestonePayment>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE672770--1410-Q0005_STD_365_20111231_0_705999x812407_712375x707810" unitRef="iso4217_USD" decimals="-5" id="id_4941002_38D211AC-7315-43E5-ACF5-C381FEEE56F2_1001_1">22500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="eol_PE672770--1410-Q0005_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_2A5E91C4-2DCD-4AF7-8280-17BE8DD72F91_1_0">8000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="eol_PE672770--1410-Q0005_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_2A5E91C4-2DCD-4AF7-8280-17BE8DD72F91_1_1">300000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE672770--1410-Q0005_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_A847B5DC-8947-41A2-BAA3-D5131D41903B_3_0">100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_90_20100331_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_0E762A67-33DE-4E9A-8867-A068B34DE4BF_2002_2">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_90_20110331_0_705999x740949_712124x770429_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_1005_0">120200000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="eol_PE672770--1410-Q0005_STD_90_20110331_0_705999x740949_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_CF908F74-C7D5-4FEE-9E35-1D87E5C10D50_1001_0">125000000</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20110630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_0E762A67-33DE-4E9A-8867-A068B34DE4BF_2003_2">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2_4">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="pure" xsi:nil="true" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2_5" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_4941002_74E1A63F-4669-47D6-9DAA-87981D219CC1_2_2">5706000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_13">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_14">51312000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_2_2">-49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_10">35000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_8">-51000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_0">324000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_2_4">-31962000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_6">-31072000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnSaleOfSecuritiesNet contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_3_2">0</us-gaap:GainLossOnSaleOfSecuritiesNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_11">-841000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_12">-31913000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_3">7324000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_5">31396000</us-gaap:OperatingExpenses>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_9">825000</us-gaap:InterestExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_4">7869000</us-gaap:RestructuringCharges>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_2_2">16203000</us-gaap:ResearchAndDevelopmentExpense>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712080x707836_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_1002_1">1000000</aveo:DecreaseInExpenseDuringThePeriod>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712080x713040_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_2002_0">6400000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2002_4">100000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_53C780B7-7A9E-4AB2-9706-AF3AF4EC597C_1002_0">7800000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_E9447C42-D6AF-4909-BFD0-FE0411782CD7_1003_0">200000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1002_0">0.7135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x711169" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1002_2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2002_1">0.7265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x716112" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2002_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_712080x707836_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_1002_1">-643000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_712080x713040_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_2002_0">33000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_712382x711585" unitRef="shares" decimals="-3" id="id_4941002_74E1A63F-4669-47D6-9DAA-87981D219CC1_1002_0">5696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_712382x715581" unitRef="shares" decimals="-3" id="id_4941002_74E1A63F-4669-47D6-9DAA-87981D219CC1_2002_1">10000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_713115x708980" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_E9FB46F7-9DF0-4A76-B974-C0B591DFF7B4_1002_0">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_713115x708980" unitRef="iso4217_USD" decimals="-5" id="id_4941002_BFA44916-6342-4664-8B04-FB622A6107BE_1003_2">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20130630_0_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_2_2">-610000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1_4">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="pure" xsi:nil="true" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1_5" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_74E1A63F-4669-47D6-9DAA-87981D219CC1_1_2">6243000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_13">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_14">51663000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_1_2">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_10">10000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_8">-2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_0">1846000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_B4A48DAD-1DC6-4EAE-AC1A-5216FC9E565C_1_4">-17963000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_6">-17465000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnSaleOfSecuritiesNet contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_4941002_B4F7DF1C-1A0D-4635-AF31-F86C71FEDECC_1_2">0</us-gaap:GainLossOnSaleOfSecuritiesNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_11">-494000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_12">-17959000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_3">4846000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_5">19311000</us-gaap:OperatingExpenses>
  <us-gaap:InterestExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_9">502000</us-gaap:InterestExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_4">5165000</us-gaap:RestructuringCharges>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_4941002_0FEE6AEF-E2D8-4202-80C7-C78B5FCEEB95_1_2">9300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_4941002_A847B5DC-8947-41A2-BAA3-D5131D41903B_1_0">5100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712080x707836_712375x1077987" unitRef="iso4217_USD" decimals="0" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_1001_2">8000</aveo:DecreaseInExpenseDuringThePeriod>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712080x713040_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_B64BC094-F216-47AB-A749-A94490DAEB20_2001_0">1100000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2001_4">1800000</us-gaap:DeferredRevenueRevenueRecognized>
  <aveo:AdditionalDeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712124x828573_712375x1077987" unitRef="iso4217_USD" decimals="-5" id="id_4941002_33E4AC6A-90DC-4143-BDD4-74B90B6BD61C_2001_3">1700000</aveo:AdditionalDeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712375x732419" unitRef="iso4217_USD" decimals="-5" id="id_4941002_53C780B7-7A9E-4AB2-9706-AF3AF4EC597C_1001_0">1200000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x840210_712375x778714" unitRef="iso4217_USD" decimals="-5" id="id_4941002_E9447C42-D6AF-4909-BFD0-FE0411782CD7_1001_0">100000</us-gaap:DeferredRevenueRevenueRecognized>
  <aveo:DecreaseInExpenseDuringThePeriod contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x891464_712080x713040_712375x891398" unitRef="iso4217_USD" decimals="-5" id="id_4941002_F9057CF0-AA7F-4E3D-9B1D-06A7F53C3C91_1001_0">200000</aveo:DecreaseInExpenseDuringThePeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x711169" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1001_0">0.7206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x711169" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_1001_2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x716112" unitRef="pure" decimals="4" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2001_1">0.7398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x716112" id="id_4941002_1EAC55BE-E704-4A7D-9370-CA37A35574BD_2001_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:BusinessExitCosts1 contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_1001_0">9200000</us-gaap:BusinessExitCosts1>
  <us-gaap:RestructuringCharges contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_1001_3">5000000</us-gaap:RestructuringCharges>
  <us-gaap:AccretionExpense contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_1001_4">300000</us-gaap:AccretionExpense>
  <us-gaap:GainLossOnContractTermination contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923_715990x770350" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_2001_2">5100000</us-gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923_715990x799157" unitRef="iso4217_USD" decimals="-5" id="id_4941002_75865038-5B33-478F-8CCA-7E83545BE0A5_3001_1">9300000</us-gaap:GainLossOnContractTermination>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_712080x707836_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_1001_1">459000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_712080x713040_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_2001_0">197000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_712382x711585" unitRef="shares" decimals="-3" id="id_4941002_74E1A63F-4669-47D6-9DAA-87981D219CC1_1001_0">6243000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_713115x708980" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4941002_E9FB46F7-9DF0-4A76-B974-C0B591DFF7B4_1001_0">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_713115x708980" unitRef="iso4217_USD" decimals="-5" id="id_4941002_BFA44916-6342-4664-8B04-FB622A6107BE_1002_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE672770--1410-Q0005_STD_91_20140630_0_713115x863784" unitRef="iso4217_USD" decimals="-3" id="id_4941002_7E9528B9-66E0-4904-857F-B5F6DC3BE3B5_1_2">656000</us-gaap:ShareBasedCompensation>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_712382x711585">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_712080x713040_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_712080x707836_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923_715990x799157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aveo:DeferredRentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923_715990x770350">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aveo:LeaseholdImprovementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_711976x715923">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x891464_712080x713040_712375x891398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiodesixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:NsclcPocTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712124x828573_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RoyaltyTerritoryDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712080x713040_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0_705999x740949_712080x707836_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_712382x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_712382x711585">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_712080x713040_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_712080x707836_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712124x828573_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RoyaltyTerritoryDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712080x713040_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0_705999x740949_712080x707836_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_91_20110630_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_90_20110331_0_705999x740949_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_90_20110331_0_705999x740949_712124x770429_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:LicenseDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_90_20100331_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_365_20111231_0_705999x812407_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:KirinBreweryCorporationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20121231_0_705999x812407_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:KirinBreweryCorporationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20121231_0_705999x740949_712124x756018_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RegulatoryMilestoneEventsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20061231_0_705999x812407_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:KirinBreweryCorporationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-12-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20100331_0_705999x812407_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:KirinBreweryCorporationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-03-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20120331_0_712080x1077456">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aveo:LoanDiscountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-03-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20090331_0_705999x840210_712124x714298_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-03-01</startDate>
      <endDate>2009-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:StVincentHospitalSydneyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712124x714298_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:StVincentHospitalSydneyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_31_20120731_0_705999x884889_712124x714218_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:StVincentHospitalSydneyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_30_20140630_0_712080x1077456">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aveo:LoanDiscountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_30_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2014-06-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_28_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2010-06-03</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2011-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712124x791210_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:CostSharingAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2011-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_28_20110228_0_705999x740949_712124x714298_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2011-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_712080x713040_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_712080x707836_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x717013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923_715990x799157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aveo:DeferredRentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923_715990x770350">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aveo:LeaseholdImprovementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711976x715923">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x891464_712080x713040_712375x891398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiodesixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:NsclcPocTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x812407_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:KirinBreweryCorporationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x828573_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RoyaltyTerritoryDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712124x770429_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:LicenseDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712080x713040_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0_705999x740949_712080x707836_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_712080x713040_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_712080x707836_713115x863784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aveo:EquityClassifiedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x840210_712375x778714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiogenIdecInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:OptionAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712375x732419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712124x828573_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RoyaltyTerritoryDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712080x713040_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0_705999x740949_712080x707836_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_181_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_1_20100602_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2010-06-02</startDate>
      <endDate>2010-06-02</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_1_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2012-03-31</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_1_20100528_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <startDate>2010-05-28</startDate>
      <endDate>2010-05-28</endDate>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_711976x717013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712989_712857x779597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">aveo:DueInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929_712857x779597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">aveo:DueInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711515">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371_712857x779597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">aveo:DueInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_710256x711371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_708293x891906">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aveo:CorporateDebtSecuritiesIncludingCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0_708293x710575">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_716469x705598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x717013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923_715990x813034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aveo:AccruedExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923_715990x716298">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_711976x715923">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929_712857x779597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">aveo:DueInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x711371_712857x779597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">aveo:DueInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_710256x711371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_708293x891906">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aveo:CorporateDebtSecuritiesIncludingCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_708293x710575">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_705999x891464_712375x891398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiodesixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:NsclcPocTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0_705999x740949_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20110331_0_705999x740949_712124x828573_712375x1077987">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:AstellasPharmaIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">aveo:RoyaltyTerritoryDeliverableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:AstellasAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20100602_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2010-06-02</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140801_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2014-08-01</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140430_0_705999x891464_712375x891398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiodesixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:NsclcPocTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-04-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20140430_0_705999x891464_711502x716112_712375x891398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:BiodesixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aveo:NsclcPocTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-04-30</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20120731_0_705999x884889_712375x707810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aveo:StVincentHospitalSydneyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-31</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20100528_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-05-28</instant>
    </period>
  </context>
  <context id="eol_PE672770--1410-Q0005_STD_0_20100528_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001325879</identifier>
    </entity>
    <period>
      <instant>2010-05-28</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>aveo:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Investment">
    <measure>aveo:Investment</measure>
  </unit>
  <unit id="Securities">
    <measure>aveo:Securities</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="LegalMatter">
    <measure>aveo:LegalMatter</measure>
  </unit>
  <unit id="Segment">
    <measure>aveo:Segment</measure>
  </unit>
</xbrl>